* Says it will set up a new JV in Inner Mongolia, with five
individuals
Read more
Monday, May 30, 2016
UPDATE 1-Samsung C&T to appeal ruling on share buyback price
SEOUL, May 31 (Reuters) - South Korea's Samsung C&T Corp
said it plans to appeal against a court ruling
ordering it to pay five shareholders more for a buyback offered
during a merger last year that consolidated stakes in Samsung
Group affiliates.
Read more
said it plans to appeal against a court ruling
ordering it to pay five shareholders more for a buyback offered
during a merger last year that consolidated stakes in Samsung
Group affiliates.
Read more
Samsung C&T to appeal against ruling on Cheil deal price
SEOUL, May 31 (Reuters) - South Korea's Samsung C&T Corp
said it plans to appeal against a court ruling
ordering it to pay a higher price for a share buyback offer made
during a merger last year that consolidated stakes in key
Samsung Group affiliates.
Read more
said it plans to appeal against a court ruling
ordering it to pay a higher price for a share buyback offer made
during a merger last year that consolidated stakes in key
Samsung Group affiliates.
Read more
DIARY-Malaysia 2016 corporate earnings
Following is a list of release dates for the quarterly earnings
of some top Malaysia-listed companies.
To submit a date, email: ananthalakshmi.as@tr.com
Company RIC PERIOD DATE
AirAsia Bhd Q1 May 26
AMMB Holdings Bhd Q4 May 20-24
Astro Malaysia Holdings Bhd Q1 Jun 14-20
Axiata Group Bhd Q1 May 25
British American Tobacco
Read more
of some top Malaysia-listed companies.
To submit a date, email: ananthalakshmi.as@tr.com
Company RIC PERIOD DATE
AirAsia Bhd Q1 May 26
AMMB Holdings Bhd Q4 May 20-24
Astro Malaysia Holdings Bhd Q1 Jun 14-20
Axiata Group Bhd Q1 May 25
British American Tobacco
Read more
BRIEF-Vitality qtrly shr loss $0.00
May 30 (Reuters) - Vitality Products Inc :
* Qtrly loss per share $0.00
* Vitality reports year end results
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom)
Read more
EQT sells Atos Medical, sources value deal at 850 mln euros
FRANKFURT, May 30 (Reuters) - Swedish buyout house EQT has
sold its medical devices business Atos Medical to private equity
firm PAI Europe, it said on Monday, with sources valuing the
deal at about 850 million euros ($946 million).
Read more
sold its medical devices business Atos Medical to private equity
firm PAI Europe, it said on Monday, with sources valuing the
deal at about 850 million euros ($946 million).
Read more
Roche and Novartis face off in biosimilar drug battle
ZURICH, May 30 (Reuters) - Switzerland's biggest drugmakers
are clashing over cheaper copies of pricey biotech drugs - one
reason why Novartis is considering selling its $14
billion stake in cross-town rival Roche.
Read more
are clashing over cheaper copies of pricey biotech drugs - one
reason why Novartis is considering selling its $14
billion stake in cross-town rival Roche.
Read more
UPDATE 1-EU to propose shorter glyphosate licence renewal -sources
* If no deal by June 30, product to be phased out
(Releads, adds more on decision process, Bayer bid)
Read more
(Releads, adds more on decision process, Bayer bid)
Read more
BRIEF-Genmab achieves $30 mln milestone in deal with Janssen
* Says milestone triggered by first commercial sale of
Darzalex in Europe
Source text for Eikon:
Further company coverage:
(Copenhagen newsroom)
Read more
Darzalex in Europe
Source text for Eikon:
Further company coverage:
(Copenhagen newsroom)
Read more
BRIEF-EQT sells Atos Medical to PAI for undisclosed amount
* Sources told Reuters earlier this month a handful of
private equity firms, including PAI, were in the second round of
bidding for Atos, adding it could be worth around 1 billion
euros
Source text for Eikon:
Read more
private equity firms, including PAI, were in the second round of
bidding for Atos, adding it could be worth around 1 billion
euros
Source text for Eikon:
Read more
EU to debate shorter glyphosate licence renewal next week - sources
BRUSSELS, May 30 (Reuters) - EU nations will debate next
week a far shorter licence renewal for weed-killer glyphosate,
used in Monsanto's Roundup, amid a transatlantic row
over whether it may cause cancer.
Read more
week a far shorter licence renewal for weed-killer glyphosate,
used in Monsanto's Roundup, amid a transatlantic row
over whether it may cause cancer.
Read more
Air travel demand slows as airlines confront security, fragile economies
BERLIN, May 30 (Reuters) - Air passenger demand in April
rose at its slowest rate since January 2015, weighed by the
March attacks on Brussels airport and highlighting safety as one
of the main challenges facing top airline executives meeting
this week.
Read more
rose at its slowest rate since January 2015, weighed by the
March attacks on Brussels airport and highlighting safety as one
of the main challenges facing top airline executives meeting
this week.
Read more
BRIEF-Phase Holographic Imaging gets follow-up order of SEK 2.8 mln
* Says has received a follow-up order for a minimum of eight motorized HoloMonitor M4
instruments, continuing the strong business performance in the Chinese market
Read more
instruments, continuing the strong business performance in the Chinese market
Read more
RPT-Alibaba tells vendors to halt drug sales online, cites government rule change
SHANGHAI, May 30 (Reuters) - Chinese e-commerce firm Alibaba
Group Holding Ltd has told vendors on its Tmall website
to stop selling medicine, saying a local regulator has issued an
"urgent" directive halting drug sales via third-party platforms.
Read more
Group Holding Ltd has told vendors on its Tmall website
to stop selling medicine, saying a local regulator has issued an
"urgent" directive halting drug sales via third-party platforms.
Read more
BRIEF-Biomm announces credit agreement for BRL 10.3 million
* Announced on Friday a credit agreement with certain
shareholders, for the total amount of 10.3 million Brazilian
reais ($2.9 million)
Read more
shareholders, for the total amount of 10.3 million Brazilian
reais ($2.9 million)
Read more
BRIEF-Harbin Gloria Pharmaceuticals to pay 2015 dividend on June 3
* Says it plans to pay a cash dividend of 2.5 yuan (before
tax) per 10 shares and distribute 10 new shares for every 10
shares as stock dividends, to shareholders of record on June 2,
for 2015
Read more
tax) per 10 shares and distribute 10 new shares for every 10
shares as stock dividends, to shareholders of record on June 2,
for 2015
Read more
Australia miners merge, hope to boost lithium sales
SYDNEY, May 30 (Reuters) - Galaxy Resources and
General Mining on Monday agreed to a A$216 million
($155 million) merger to consolidate their lithium mines in
Australia, Canada and Argentina, with prices for the metal
soaring on growing demand for electric vehicles.
Read more
General Mining on Monday agreed to a A$216 million
($155 million) merger to consolidate their lithium mines in
Australia, Canada and Argentina, with prices for the metal
soaring on growing demand for electric vehicles.
Read more
BRIEF-Shanxi Zhendong Pharmaceutical to pay 2015 dividend on June 6
* Says it will pay cash dividend of 5.819357 yuan per 10
shares (before tax), revised from 6 yuan per 10 shares due to
equity incentive, to shareholders of record on June 3 for 2015
Read more
shares (before tax), revised from 6 yuan per 10 shares due to
equity incentive, to shareholders of record on June 3 for 2015
Read more
CORRECTED-Samsung Bioepis receives final European approval for its Remicade copy
SEOUL, May 30 (Reuters) - South Korea's Samsung Bioepis said
on Monday its biosimilar of Johnson & Johnson's
blockbuster rheumatoid arthritis drug Remicade has received
final approval from European regulators, paving the way for its
second product launch in Europe.
Read more
on Monday its biosimilar of Johnson & Johnson's
blockbuster rheumatoid arthritis drug Remicade has received
final approval from European regulators, paving the way for its
second product launch in Europe.
Read more
How Wellcome and Gates charities profit from helping biotech
LONDON, May 30 (Reuters) - The Wellcome Trust medical
charity is to profit from U.S. approval of a new diagnostic
cancer test, the first commercial product funded by the
organisation since the sale of its pharmaceuticals business to
Glaxo in 1995.
Read more
charity is to profit from U.S. approval of a new diagnostic
cancer test, the first commercial product funded by the
organisation since the sale of its pharmaceuticals business to
Glaxo in 1995.
Read more
Sunday, May 29, 2016
BRIEF-UCB announces new clinical trial data on lacosamide
* Says new clinical trial data, presented at the second
Congress of the European Academy of Neurology, showed
non-inferiority of lacosamide (VIMPAT) monotherapy compared with
controlled-release carbamazepine among patients with newly or
recently diagnosed focal epilepsy
Source text: http://bit.ly/1slGMaJ
Further company coverage:
(Gdynia Newsroom)
Read more
Congress of the European Academy of Neurology, showed
non-inferiority of lacosamide (VIMPAT) monotherapy compared with
controlled-release carbamazepine among patients with newly or
recently diagnosed focal epilepsy
Source text: http://bit.ly/1slGMaJ
Further company coverage:
(Gdynia Newsroom)
Read more
BRIEF-Sunflower Pharmaceutical Group to boost stake in unit for 43 mln yuan
* Says it plans to buy 5 million worth of equity in a
Hengshui-based controlling pharmacy unit from an individual for
43 million yuan, and to boost stake in the unit to 77.1429
percent from 70 percent
Read more
Hengshui-based controlling pharmacy unit from an individual for
43 million yuan, and to boost stake in the unit to 77.1429
percent from 70 percent
Read more
BRIEF-Sunflower Pharmaceutical Group to set up wholly owned unit
* Says it plans to invest 50 million yuan to set up a wholly
owned health technology subsidiary in Chongqing
Read more
owned health technology subsidiary in Chongqing
Read more
BRIEF-North China Pharmaceutical gets GMP certificate
* Says it receives goods manufacture practice (GMP)
certificate from Hebei Food and Drug Administration
Read more
certificate from Hebei Food and Drug Administration
Read more
DIARY-Malaysia 2016 corporate earnings
Following is a list of release dates for the quarterly earnings
of some top Malaysia-listed companies.
To submit a date, email: ananthalakshmi.as@tr.com
Company RIC PERIOD DATE
AirAsia Bhd Q1 May 26
AMMB Holdings Bhd Q4 May 20-24
Astro Malaysia Holdings Bhd Q1 Jun 14-20
Axiata Group Bhd Q1 May 25
British American Tobacco
Read more
of some top Malaysia-listed companies.
To submit a date, email: ananthalakshmi.as@tr.com
Company RIC PERIOD DATE
AirAsia Bhd Q1 May 26
AMMB Holdings Bhd Q4 May 20-24
Astro Malaysia Holdings Bhd Q1 Jun 14-20
Axiata Group Bhd Q1 May 25
British American Tobacco
Read more
New incentives needed to develop antibiotics to fight superbugs
NEW YORK, May 27 (Reuters) - Drugmakers are renewing efforts
to develop medicines to fight emerging antibiotic-resistant
bacteria, but creating new classes of drugs on the scale needed
is unlikely to happen without new financial incentives to make
the effort worth the investment, companies and industry experts
said.
Read more
to develop medicines to fight emerging antibiotic-resistant
bacteria, but creating new classes of drugs on the scale needed
is unlikely to happen without new financial incentives to make
the effort worth the investment, companies and industry experts
said.
Read more
India's Sun Pharma gets U.S. subpoena over generic drugs pricing
MUMBAI, May 28 (Reuters) - The U.S. Department of Justice
(DoJ) has subpoenaed India's largest drugmaker Sun
Pharmaceutical Industries Ltd seeking information about
the pricing and marketing of the generic drugs it sells in the
United States, the company said on Saturday.
Read more
(DoJ) has subpoenaed India's largest drugmaker Sun
Pharmaceutical Industries Ltd seeking information about
the pricing and marketing of the generic drugs it sells in the
United States, the company said on Saturday.
Read more
Friday, May 27, 2016
New incentives needed to develop antibiotics to fight superbugs
NEW YORK, May 27 (Reuters) - Drugmakers are renewing efforts
to develop medicines to fight emerging antibiotic-resistant
bacteria, but creating new classes of drugs on the scale needed
is unlikely to happen without new financial incentives to make
the effort worth the investment, companies and industry experts
said.
Read more
to develop medicines to fight emerging antibiotic-resistant
bacteria, but creating new classes of drugs on the scale needed
is unlikely to happen without new financial incentives to make
the effort worth the investment, companies and industry experts
said.
Read more
BRIEF-Trovagene files for mixed shelf of up to $250 million
* Files for mixed shelf of up to $250 million - SEC filing
Source text for Eikon:
Further company coverage:
Read more
Source text for Eikon:
Further company coverage:
Read more
BRIEF-Osiris Therapeutics says being investigated by NY Attorney's Office
* Advised by U.S. Attorney's Office for Southern District of
New York that criminal investigation has been opened into co
Read more
New York that criminal investigation has been opened into co
Read more
UPDATE 1-Biogen, AbbVie once-monthly MS injection wins U.S. approval
May 27 (Reuters) - The U.S. Food and Drug Administration on
Friday approved a once-monthly injection for multiple sclerosis
from Biogen Inc and AbbVie Inc, with a boxed
warning.
Read more
Friday approved a once-monthly injection for multiple sclerosis
from Biogen Inc and AbbVie Inc, with a boxed
warning.
Read more
BRIEF-S&P Dow Jones Indices says Transdigm Group will replace Baxalta Inc in the S&P 500
* Transdigm Group Inc will replace Baxalta Inc in the S&P
500 after the close of trading on Thursday, June 2
Source text - http://bit.ly/22roP74
(Bengaluru Newsroom: +1 646 223 8780)
Read more
500 after the close of trading on Thursday, June 2
Source text - http://bit.ly/22roP74
(Bengaluru Newsroom: +1 646 223 8780)
Read more
UN urges Syrian government to stop blocking aid deliveries
UNITED NATIONS, May 27 (Reuters) - The United Nations'
humanitarian chief on Friday demanded that the Syrian government
and militant groups stop interfering with the delivery of food
and medicine for civilians trapped in besieged and
difficult-to-reach areas in war-ravaged Syria.
Read more
humanitarian chief on Friday demanded that the Syrian government
and militant groups stop interfering with the delivery of food
and medicine for civilians trapped in besieged and
difficult-to-reach areas in war-ravaged Syria.
Read more
DEALTALK-How four words rewrote Bayer-Monsanto deal script
Monsanto Co President Brett Begemann uttered those
words last week to a small group of investors and a Reuters
reporter when asked how the world's largest seed company he
helps lead might fit with German drugs and crop chemicals group
Bayer AG.
Read more
words last week to a small group of investors and a Reuters
reporter when asked how the world's largest seed company he
helps lead might fit with German drugs and crop chemicals group
Bayer AG.
Read more
UPDATE 1-Delay or move Rio Olympics due to Zika - medical experts
LONDON, May 27 (Reuters) - More than 100 health experts have called for the Rio Olympic Games to be postponed or moved because of fears that the event could speed up the spread of the Zika virus around the world, according to a public letter published online.
Read more
Read more
Deals of the day- Mergers and acquisitions
May 27 (Reuters) - The following bids, mergers, acquisitions
and disposals were reported by 2000 GMT on Friday:
Read more
and disposals were reported by 2000 GMT on Friday:
Read more
BRIEF-Sofinnova Venture Partners reports 9.1 pct stake in Merus BV
* Sofinnova Venture Partners reports 9.1 pct stake in Merus
as of may 19 - sec filing
Source text: http://1.usa.gov/1VlVkSQ
Further company coverage:
(Bengaluru Newsroom +91 80 6749-1130; within U.S. +1 646 223
8780)
Read more
as of may 19 - sec filing
Source text: http://1.usa.gov/1VlVkSQ
Further company coverage:
(Bengaluru Newsroom +91 80 6749-1130; within U.S. +1 646 223
8780)
Read more
BRIEF-Cytrx Corp issued 1.6 mln shares for benefit of claimants of IN RE Cytrx securities litigation
* Cytrx Corp says on May 25, 2016, issued for benefit of
claimants in matter of IN RE Cytrx Securities litigation total
of 1.6 million shares of stock
Read more
claimants in matter of IN RE Cytrx Securities litigation total
of 1.6 million shares of stock
Read more
European shares advance as Roche rally lifts pharma stocks
* Banks impacted by slump at Spain's Banco Popular
(ADVISORY- Reuters plans to replace intra-day European and UK
stock market reports with a Live Markets blog on Eikon - see cpurl://apps.cp./cms/?pageId=livemarkets
for site in development. See the bottom of the report for more
details) Adds details, prices)
Read more
(ADVISORY- Reuters plans to replace intra-day European and UK
stock market reports with a Live Markets blog on Eikon - see cpurl://apps.cp./cms/?pageId=livemarkets
for site in development. See the bottom of the report for more
details) Adds details, prices)
Read more
GSK gets EU approval for first gene therapy for children
LONDON, May 27 (Reuters) - The world's first life-saving
gene therapy for children, developed by GlaxoSmithKline
and Italian scientists, was approved for sale in Europe on
Friday, in a step forward for the pioneering technology to fix
faulty genes.
Read more
gene therapy for children, developed by GlaxoSmithKline
and Italian scientists, was approved for sale in Europe on
Friday, in a step forward for the pioneering technology to fix
faulty genes.
Read more
Monsanto boss could net $70 million from a Bayer takeover
LONDON, May 27 (Reuters) - Monsanto boss Hugh Grant could
land more than $70 million if the world's largest seed company
is taken over by German chemicals giant Bayer AG.
Read more
land more than $70 million if the world's largest seed company
is taken over by German chemicals giant Bayer AG.
Read more
UPDATE 1-Thai queen undergoes medical tests, palace says in rare statement
BANGKOK, May 27 (Reuters) - Thailand's 83-year-old Queen
Sirikit has undergone medical tests and has "insufficient blood
in the brain", the Royal Household Bureau said in a rare
statement on her health on Friday.
Read more
Sirikit has undergone medical tests and has "insufficient blood
in the brain", the Royal Household Bureau said in a rare
statement on her health on Friday.
Read more
BRIEF-Intellipharmaceutics announces pricing of $5.2 mln public offering
* Intellipharmaceutics announces pricing of $5.2 million
public offering of common shares and warrants
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1 646 223 8780)
Read more
public offering of common shares and warrants
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1 646 223 8780)
Read more
BRIEF-4SC AG gives headline results from Phase II trial of resminostat
* 4SC provides headline results from Yakult Honsha's Phase II trial of resminostat in
combination with sorafenib as first line therapy in liver cancer
Source text for Eikon:
Further company coverage:
(Gdynia Newsroom)
Read more
combination with sorafenib as first line therapy in liver cancer
Source text for Eikon:
Further company coverage:
(Gdynia Newsroom)
Read more
BRIEF-Takeda Pharmaceutical Co Ltd receives positive CHMP opinion for ADCETRIS
* Takeda receives positive CHMP opinion for ADCETRIS as
consolidation treatment in post-transplant hodgkin lymphoma
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1 646 223 8780)
Read more
consolidation treatment in post-transplant hodgkin lymphoma
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1 646 223 8780)
Read more
UPDATE 1-Thermo Fisher to buy microscope maker FEI Co for about $4.2 bln
May 27 (Reuters) - Thermo Fisher Scientific Inc, the
world's largest maker of scientific instruments, said it would
buy FEI Co for about $4.2 billion to gain access to the
company's electron microscopy technology that helps studying
proteins.
Read more
world's largest maker of scientific instruments, said it would
buy FEI Co for about $4.2 billion to gain access to the
company's electron microscopy technology that helps studying
proteins.
Read more
BRIEF-Merck receives positive CHMP opinion for Zepatier in the EU
* Merck receives positive CHMP opinion for Zepatier(tm)
(Elbasvir and Grazoprevir) in the European Union
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
(Elbasvir and Grazoprevir) in the European Union
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
Thermo Fisher to buy FEI Co for about $4.2 bln
May 27 (Reuters) - Thermo Fisher Scientific Inc said
it would buy FEI Co for about $4.2 billion to gain
access to its signature electron microscopy technology.
Read more
it would buy FEI Co for about $4.2 billion to gain
access to its signature electron microscopy technology.
Read more
BRIEF-AbbVie's Humira receives CHMP positive opinion to treat non-infectious uveitis
* AbbVie's Humira receives CHMP positive opinion to treat
certain forms of non-infectious uveitis, a disease that can
severely impact vision
Read more
certain forms of non-infectious uveitis, a disease that can
severely impact vision
Read more
REFILE-European shares inch lower ahead of Yellen; Roche rallies
MILAN, May 27 (Reuters) - European shares fell slightly on
Friday, weighed down by weakness in Spanish banks and some oil
sector stocks, although Roche soared on positive results
from an interim analysis of one of its cancer drugs.
Read more
Friday, weighed down by weakness in Spanish banks and some oil
sector stocks, although Roche soared on positive results
from an interim analysis of one of its cancer drugs.
Read more
BRIEF-Yungshin Pharm. Ind. unit to fully acquire biotechnology company at T$805.6 mln
* Says its pharmaceutical subsidiary to fully acquire a
biotechnology company at T$805.6 million from Zoetis Holdings
LLC, Taiwan Sugar Corporation and an individual
Read more
biotechnology company at T$805.6 million from Zoetis Holdings
LLC, Taiwan Sugar Corporation and an individual
Read more
UPDATE 1-AstraZeneca potassium drug delayed by manufacturing snag
LONDON, May 27 (Reuters) - AstraZeneca said on
Friday U.S. regulators would not approve its new drug for high
potassium levels at present due to a manufacturing issue,
dealing a blow to a product acquired when it bought ZS Pharma
for $2.7 billion last year.
Read more
Friday U.S. regulators would not approve its new drug for high
potassium levels at present due to a manufacturing issue,
dealing a blow to a product acquired when it bought ZS Pharma
for $2.7 billion last year.
Read more
European shares slip as energy and bank stocks fall
MILAN, May 27 (Reuters) - European shares fell slightly in
early trading on Friday, weighed down by weaker oil sector
stocks and Spanish banks, although Roche soared on
positive results from an interim analysis of one of its drugs.
Read more
early trading on Friday, weighed down by weaker oil sector
stocks and Spanish banks, although Roche soared on
positive results from an interim analysis of one of its drugs.
Read more
BRIEF-Bioton dismisses CEO
* Said on Thursday that its supervisory board resolved to
dismiss the company's CEO, Slawomir Ziegert, as of May 30
Read more
dismiss the company's CEO, Slawomir Ziegert, as of May 30
Read more
BRIEF-AstraZeneca announces positive results in breast cancer trial
* Announced positive results from phase III falcon trial
comparing faslodex 500mg (fulvestrant) to arimidex 1mg
Read more
comparing faslodex 500mg (fulvestrant) to arimidex 1mg
Read more
Thursday, May 26, 2016
BRIEF-Edan Instruments says 2015 dividend payment date
* Says it will pay a cash dividend of 2.1 yuan (pre-tax) for
every 10 shares and use additional paid-in capital to distribute
15 new shares for every 10 shares, to shareholders of record on
May 31 for 2015
Read more
every 10 shares and use additional paid-in capital to distribute
15 new shares for every 10 shares, to shareholders of record on
May 31 for 2015
Read more
BRIEF-SOBI says enters new credit facility, redeems bond loan
* SOBI enters new credit facility and redeems SEK 800 mln
bond loan 2012/2017 prior to final maturity
Source text for Eikon:
Further company coverage:
Read more
bond loan 2012/2017 prior to final maturity
Source text for Eikon:
Further company coverage:
Read more
HK Exchange says 10 firms buy back shares
HONG KONG, May 27 (Reuters) - The Hong Kong stock exchange said on Friday 10
companies had repurchased their ordinary shares in the market.
The following is a table regarding share buybacks:
Company name Date of No. of Highest Lowest
(Stock code) Repurchase Securities Price per Price per
Repurchased share share
ALLIED PPT (HK) 2016/05/26 192,000 HK$1.46 N/A
Read more
companies had repurchased their ordinary shares in the market.
The following is a table regarding share buybacks:
Company name Date of No. of Highest Lowest
(Stock code) Repurchase Securities Price per Price per
Repurchased share share
ALLIED PPT (HK) 2016/05/26 192,000 HK$1.46 N/A
Read more
BRIEF-ScinoPharm Taiwan unit signs credit line agreement of 300 mln yuan
* Says its Changshu-based medical subsidiary signed an
agreement for syndicated credit line of 300 million yuan, with a
term of 3 years
Read more
agreement for syndicated credit line of 300 million yuan, with a
term of 3 years
Read more
UPDATE 1-Theranos sued over blood tests, in proposed class action
May 26 (Reuters) - Blood-testing company Theranos Inc was
sued on Thursday, accused of endangering customer health through
"massive failures" that misrepresented the accuracy and quality
of its blood tests, according to court papers.
Read more
sued on Thursday, accused of endangering customer health through
"massive failures" that misrepresented the accuracy and quality
of its blood tests, according to court papers.
Read more
UPDATE 1-Valeant rejected joint takeover bid from Takeda, TPG in spring-WSJ
May 26 (Reuters) - Valeant Pharmaceuticals International Inc
received a joint takeover offer from Japan's Takeda
Pharmaceutical Co Ltd and TPG Capital Management LP
this spring that the Canadian drugmaker rejected, the
Wall Street Journal reported, citing people familiar with the
matter.
Read more
received a joint takeover offer from Japan's Takeda
Pharmaceutical Co Ltd and TPG Capital Management LP
this spring that the Canadian drugmaker rejected, the
Wall Street Journal reported, citing people familiar with the
matter.
Read more
UPDATE 3-U.S. sees first case of bacteria resistant to all antibiotics
May 26 (Reuters) - U.S. health officials on Thursday
reported the first case in the country of a patient with an
infection resistant to all known antibiotics, and expressed
grave concern that the superbug could pose serious danger for
routine infections if it spreads.
Read more
reported the first case in the country of a patient with an
infection resistant to all known antibiotics, and expressed
grave concern that the superbug could pose serious danger for
routine infections if it spreads.
Read more
BRIEF-Nobilis Health announces board nominations for shareholder meeting
* Nobilis announces board nominations for June 28th
shareholder meeting
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
shareholder meeting
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
BRIEF-Xtant Medical says new credit facility with Silicon Valley Bank
* Completion of an accounts receivable revolver credit
facility with Silicon Valley Bank to provide up to $6 million in
funds to company
Read more
facility with Silicon Valley Bank to provide up to $6 million in
funds to company
Read more
BRIEF-Aviragen delays further enrollment phase 2A trial for drug to treat RSV infections
* Voluntarily decided to delay further enrollment in phase
2a trial of bta585 for treatment of RSV infections being
conducted in U.K
Read more
2a trial of bta585 for treatment of RSV infections being
conducted in U.K
Read more
Anacor reveals receiving rival bid before Pfizer deal - filing
May 26 (Reuters) - Anacor Pharmaceuticals Inc said
it had received a takeover bid from a third party before it
struck a $5.2 billion deal with Pfizer Inc last week.
Read more
it had received a takeover bid from a third party before it
struck a $5.2 billion deal with Pfizer Inc last week.
Read more
UPDATE 1-Philips Lighting unit valued at 3.0 billion euros in IPO
AMSTERDAM, May 26 (Reuters) - Philips said on
Thursday it has set pricing in the initial public offering of
its lighting division at 20 euros per share.
Read more
Thursday it has set pricing in the initial public offering of
its lighting division at 20 euros per share.
Read more
Toronto police raid marijuana stores in latest Canada crackdown
TORONTO, May 26 (Reuters) - Toronto police have started
raiding and shutting down some marijuana dispensaries in
Canada's largest city, a spokesman said on Thursday, the latest
crackdown by local authorities as the federal government moves
to legalize the drug.
Read more
raiding and shutting down some marijuana dispensaries in
Canada's largest city, a spokesman said on Thursday, the latest
crackdown by local authorities as the federal government moves
to legalize the drug.
Read more
U.S. FDA approves first-ever implant to treat opioid addiction
May 26 (Reuters) - The first-ever implant to fight addiction
to opioids, a class of drugs that includes prescription
painkillers and heroin, was approved by the U.S. Food and Drug
Administration on Thursday.
Read more
to opioids, a class of drugs that includes prescription
painkillers and heroin, was approved by the U.S. Food and Drug
Administration on Thursday.
Read more
RPT-COLUMN-Not junk mail: Social Security letter can cut Medicare costs
CHICAGO, May 26 (Reuters) - A letter arrives in the mail
with this opening line: "We are writing to let you know how you
can get help paying your Medicare costs." Your fraud detector
probably goes on high alert - the mailboxes of retirees
routinely are stuffed with bogus come-ons.
Read more
with this opening line: "We are writing to let you know how you
can get help paying your Medicare costs." Your fraud detector
probably goes on high alert - the mailboxes of retirees
routinely are stuffed with bogus come-ons.
Read more
BRIEF-Resources needed for effective US Zika response-CDC director
* US CDC director Frieden says narrow window to scale up effective Zika prevention in us is closing
Read more
Read more
UPDATE 2-Starboard seeks Depomed special shareholder meeting
May 26 (Reuters) - Activist investor Starboard Value LP on
Thursday formally called for a special meeting of Depomed Inc
shareholders as it looks to replace the drugmaker' s
board.
Read more
Thursday formally called for a special meeting of Depomed Inc
shareholders as it looks to replace the drugmaker' s
board.
Read more
BRIEF-MEDIANA to invest 7.15 bln won to acquire properties
* Says it will acquire land and building located in
Gyeonggi-do Province, from Korea Land & Housing Corporation
Read more
Gyeonggi-do Province, from Korea Land & Housing Corporation
Read more
UPDATE 2-Valeant appoints Tyco's Sam Eldessouky corporate controller
May 26 (Reuters) - Valeant Pharmaceuticals International Inc
appointed Tyco International Plc executive Sam
Eldessouky as corporate controller as the Canadian drugmaker
works to rebuild its reputation amid criticism of its accounting
methods.
Read more
appointed Tyco International Plc executive Sam
Eldessouky as corporate controller as the Canadian drugmaker
works to rebuild its reputation amid criticism of its accounting
methods.
Read more
Bosnia region to sell stake in top insurer on June 23
SARAJEVO, May 26 (Reuters) - Bosnia's autonomous
Bosniak-Croat Federation will offer for sale its 45.5 percent
stake in insurer Sarajevo Osiguranje on June 23,
hoping to raise at least 27.4 million Bosnian marka ($15.6
million) to help cover its budget deficit.
Read more
Bosniak-Croat Federation will offer for sale its 45.5 percent
stake in insurer Sarajevo Osiguranje on June 23,
hoping to raise at least 27.4 million Bosnian marka ($15.6
million) to help cover its budget deficit.
Read more
BRIEF-Inventiv elects David Southwell to company's board of directors
* Inventiv Health elects David Southwell to company's board
of directors
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
of directors
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
BRIEF-Tonix to present data from Phase 2 clinical study of TNX-102 SL
* Will present positive data from Phase 2 dose-finding
clinical study of TNX-102 SL for treatment of military-related
PTSD
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
clinical study of TNX-102 SL for treatment of military-related
PTSD
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
BRIEF-Milestone Scientific announces completion of clinical trial enrollment for epidural instrument
* Milestone Scientific announces completion of enrollment in
clinical trials for its epidural instrument
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
clinical trials for its epidural instrument
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
From hardy pigs to super-crops, gene editing poses new EU dilemma
LONDON, May 26 (Reuters) - Heat-tolerant Angus beef cattle
designed for the tropics with white coats instead of black or
red. A button mushroom that doesn't turn brown. Pigs that don't
fall sick.
Read more
designed for the tropics with white coats instead of black or
red. A button mushroom that doesn't turn brown. Pigs that don't
fall sick.
Read more
BRIEF-Flexion Therapeutics receives positive guidance from FDA on Zilretta NDA
* Flexion Therapeutics receives positive guidance from FDA
on new drug application (NDA) submission for Zilretta for
osteoarthritis of the knee
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
on new drug application (NDA) submission for Zilretta for
osteoarthritis of the knee
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
BRIEF-Shenzhen Neptunus Bioengineering plans project company to invest in US firm
* Says it plans to set up project company to invest $25
million in U.S. pharma firm Provision Healthcare
Read more
million in U.S. pharma firm Provision Healthcare
Read more
BRIEF-Cigna to reaffirm projected FY 2016 consolidated adjusted EPS from operations
* To reaffirm projected full year 2016 consolidated adjusted
income from operations per share, which remains in range of
$8.95 to $9.35
Source text for Eikon: [ID:(http://1.usa.gov/1TBKQua
)]
Further company coverage:
(Bengaluru Newsroom: +1 646 223 8780)
Read more
income from operations per share, which remains in range of
$8.95 to $9.35
Source text for Eikon: [ID:(http://1.usa.gov/1TBKQua
)]
Further company coverage:
(Bengaluru Newsroom: +1 646 223 8780)
Read more
BRIEF-Tonghua Dongbao Pharmaceutical to pay 2015 dividend on June 3
* Says it to pay cash dividend of 2 yuan per 10 shares
(before tax) to shareholders of record on June 2 for 2015
Read more
(before tax) to shareholders of record on June 2 for 2015
Read more
BRIEF-Olainfarm AS plans to increase sales of Sia Tonus Elast to EUR 9 million IN 2016
* Plans that sales of Sia Tonus Elast in 2016 could increase to 9 million euros ($10.05
million)
Read more
million)
Read more
UPDATE 1-S. Korea picks GE to supply engines for homegrown fighter jets
* S.Korea plans to localise engine part production
(Add jet project details, industry background)
Read more
(Add jet project details, industry background)
Read more
Wednesday, May 25, 2016
BRIEF-Ablynx to present a post-hoc analysis of the PHASE II TITAN study with caplacizumab
* Ablynx to present a post-hoc analysis of the Phase II
TITAN study with caplacizumab in acquired TTP patients at the
21st congress of the European hematology association
Read more
TITAN study with caplacizumab in acquired TTP patients at the
21st congress of the European hematology association
Read more
UPDATE 1-Singapore factory output grows at fastest pace in nearly 2 years
SINGAPORE, May 26 (Reuters) - Singapore's industrial
production in April grew at the fastest pace in nearly two years
thanks to healthy output of electronics and pharmaceuticals, but
analysts remain wary over the outlook due to sluggish global
demand.
Read more
production in April grew at the fastest pace in nearly two years
thanks to healthy output of electronics and pharmaceuticals, but
analysts remain wary over the outlook due to sluggish global
demand.
Read more
BRIEF-Reata Pharmaceuticals 5.5 mln shares priced at $11 per share
* Announced pricing of its initial public offering of
5,500,000 shares of its class a common stock at $11 per share
Read more
5,500,000 shares of its class a common stock at $11 per share
Read more
HK Exchange says 11 firms buy back shares
HONG KONG, May 26 (Reuters) - The Hong Kong stock exchange said on Thursday
11 companies had repurchased their ordinary shares in the market.
The following is a table regarding share buybacks:
Company name Date of No. of Highest Lowest
(Stock code) Repurchase Securities Price per Price per
Repurchased share share
ALLIED GROUP 25/05/2016 2,000 HK$38.2 N/A
Read more
11 companies had repurchased their ordinary shares in the market.
The following is a table regarding share buybacks:
Company name Date of No. of Highest Lowest
(Stock code) Repurchase Securities Price per Price per
Repurchased share share
ALLIED GROUP 25/05/2016 2,000 HK$38.2 N/A
Read more
DIARY-Malaysia 2016 corporate earnings
Following is a list of release dates for the quarterly earnings
of some top Malaysia-listed companies.
To submit a date, email: ananthalakshmi.as@tr.com
Company RIC PERIOD DATE
AirAsia Bhd Q1 May 26
AMMB Holdings Bhd Q4 May 20-24
Astro Malaysia Holdings Bhd Q1 Jun 14-20
Axiata Group Bhd Q1 May 25
British American Tobacco
Read more
of some top Malaysia-listed companies.
To submit a date, email: ananthalakshmi.as@tr.com
Company RIC PERIOD DATE
AirAsia Bhd Q1 May 26
AMMB Holdings Bhd Q4 May 20-24
Astro Malaysia Holdings Bhd Q1 Jun 14-20
Axiata Group Bhd Q1 May 25
British American Tobacco
Read more
BRIEF-Ventas says priced $400 mln of 3.125% senior notes due 2023
* Says priced a public offering of $400 million aggregate
principal amount of 3.125% senior notes due 2023
Read more
principal amount of 3.125% senior notes due 2023
Read more
BRIEF-FDA recommends approval of Sanofi treatment for Type 2 Diabetes
* FDA advisory committee recommends approval of Sanofi
treatment for adults with Type 2 Diabetes
Read more
treatment for adults with Type 2 Diabetes
Read more
UPDATE 2-Aetna-Humana tie-up is anti-competitive in Missouri-state regulator
May 25 (Reuters) - A tie-up of Aetna Inc and Humana
Inc would be anti-competitive in Missouri for several
types of insurance, including individual Medicare Advantage
plans where the combined company would have more than a 50
percent market share, the Missouri Department of Insurance said.
Read more
Inc would be anti-competitive in Missouri for several
types of insurance, including individual Medicare Advantage
plans where the combined company would have more than a 50
percent market share, the Missouri Department of Insurance said.
Read more
UPDATE 1-South Carolina governor to sign ban on abortion past 19 weeks
CHARLESTON, Texas, May 25 (Reuters) - Republican South
Carolina Governor Nikki Haley on Wednesday signed into law a
bill banning most abortions after 19 weeks of pregnancy unless
the mother's life is at risk, a spokesperson told Reuters on
Wednesday.
Read more
Carolina Governor Nikki Haley on Wednesday signed into law a
bill banning most abortions after 19 weeks of pregnancy unless
the mother's life is at risk, a spokesperson told Reuters on
Wednesday.
Read more
COLUMN-We need to fight Zika the way governments fight terror
May 25 (Reuters) - The Zika virus exploded out of Brazilian
slums at 21st-century speeds, and raced north into Central
America and the Caribbean in a matter of months. A full-blown
outbreak in the United States looks imminent.
Read more
slums at 21st-century speeds, and raced north into Central
America and the Caribbean in a matter of months. A full-blown
outbreak in the United States looks imminent.
Read more
BRIEF-Amgen announces pricing terms of senior notes exchange offers
* Amgen announces pricing terms of senior notes exchange
offers
Source text for Eikon:
Further company coverage:
Read more
offers
Source text for Eikon:
Further company coverage:
Read more
UPDATE 1-U.S. panel backs approval of Sanofi combination diabetes drug
May 25 (Reuters) - One day after recommending approval of a
new diabetes drug made by Novo Nordisk A/S, a U.S.
advisory panel on Wednesday recommended approval of a similar
product made by Sanofi SA.
Read more
new diabetes drug made by Novo Nordisk A/S, a U.S.
advisory panel on Wednesday recommended approval of a similar
product made by Sanofi SA.
Read more
UPDATE 1-Philips Lighting IPO price may top 20 euros - sources
AMSTERDAM, May 25 (Reuters) - Shares in the initial public
offering of Philips' Lighting division could price
above 20 euros, people familiar with the matter said on
Wednesday.
Read more
offering of Philips' Lighting division could price
above 20 euros, people familiar with the matter said on
Wednesday.
Read more
Fitch Rates Ventas' Senior Unsecured Notes due 2023 'BBB+'; Outlook Stable
(The following statement was released by the rating agency)
NEW YORK, May 25 (Fitch) Fitch Ratings has assigned a 'BBB+'
rating to the
senior unsecured notes due 2023 issued by Ventas Realty, L.P.
(Issuer Default
Rating 'BBB+'/Outlook Stable), the operating partnership
of Ventas, Inc.
(NYSE: VTR). A full list of ratings follows at the end of this
release.
KEY RATING DRIVERS
The 'BBB+' rating and Stable Outlook reflect Ventas' diverse
portfolio of
healthcare properties, demonstrated and cons
Read more
NEW YORK, May 25 (Fitch) Fitch Ratings has assigned a 'BBB+'
rating to the
senior unsecured notes due 2023 issued by Ventas Realty, L.P.
(Issuer Default
Rating 'BBB+'/Outlook Stable), the operating partnership
of Ventas, Inc.
(NYSE: VTR). A full list of ratings follows at the end of this
release.
KEY RATING DRIVERS
The 'BBB+' rating and Stable Outlook reflect Ventas' diverse
portfolio of
healthcare properties, demonstrated and cons
Read more
BRIEF-Txcell obtains authorization to restart Ovasave Phase IIb clinical trial
* Txcell obtains authorization from European regulatory authorities to restart Ovasave Phase
IIb clinical trial
Source text for Eikon:
Further company coverage:
(Gdynia Newsroom)
Read more
IIb clinical trial
Source text for Eikon:
Further company coverage:
(Gdynia Newsroom)
Read more
BRIEF-Txcell obtains authorization to restart Ovasave phase IIb clinical trial
* Obtains authorization from European regulatory authorities
to restart Ovasave phase IIb clinical trial
Source text for Eikon:
Further company coverage:
(Gdynia Newsroom)
Read more
to restart Ovasave phase IIb clinical trial
Source text for Eikon:
Further company coverage:
(Gdynia Newsroom)
Read more
Qatar cuts spending on new health facilities - official
DUBAI, May 25 (Reuters) - Qatar has cut its planned spending
on building healthcare facilities by about two-thirds this year
following the drop in energy prices but expenditure on its World
Cup-related projects should be unchanged, an official said on
Wednesday.
Read more
on building healthcare facilities by about two-thirds this year
following the drop in energy prices but expenditure on its World
Cup-related projects should be unchanged, an official said on
Wednesday.
Read more
UPDATE 1-Israeli firms team up for high-speed 3D stem cell printing
JERUSALEM, May 25 (Reuters) - Israeli 3D printer firm Nano
Dimension has successfully lab-tested a 3D bioprinter
for stem cells, paving the way for the potential printing of
large tissues and organs, the company said on Wednesday.
Read more
Dimension has successfully lab-tested a 3D bioprinter
for stem cells, paving the way for the potential printing of
large tissues and organs, the company said on Wednesday.
Read more
BRIEF-Medivation says urges stockholders to reject Sanofi's attempt to replace co's board of directors
* Medivation urges stockholders to reject sanofi's attempt
to replace medivation board of directors
Read more
to replace medivation board of directors
Read more
BRIEF-B. Braun's stake in Rhoen-Klinikum rises to 20 pct
* Says shareholder B. Braun's holding in company has risen
to just over 20 percent versus 18.01 percent
Source text for Eikon:
Further company coverage:
Read more
to just over 20 percent versus 18.01 percent
Source text for Eikon:
Further company coverage:
Read more
BRIEF-Spero Therapeutics to acquire worldwide rights to Vertex's VXC-486/VXC-100
* Deal to acquire worldwide rights to VXC-486/VXC-100 and a
portfolio of innovative antibacterial compounds
Read more
portfolio of innovative antibacterial compounds
Read more
Israeli firms develop high-speed 3D printer for stem cells
JERUSALEM, May 25 (Reuters) - Israeli 3D printer firm Nano
Dimension has successfully lab-tested a 3D bioprinter
for stem cells, paving the way for the potential printing of
large tissues and organs, the company said on Wednesday.
Read more
Dimension has successfully lab-tested a 3D bioprinter
for stem cells, paving the way for the potential printing of
large tissues and organs, the company said on Wednesday.
Read more
BRIEF-Latvijas Juras constructs new generation radiology dept
* Starts construction of new generation radiology department
by investing 1.1 million euros ($1.23 million)
Read more
by investing 1.1 million euros ($1.23 million)
Read more
BRIEF-Chiome Bioscience gets patent license
* Says it gets patent license in Europe for METHOD OF
INDUCING HOMOLOGOUS RECOMBINATION OF SOMATIC CELL
Read more
INDUCING HOMOLOGOUS RECOMBINATION OF SOMATIC CELL
Read more
BRIEF-GSK says gene therapy for immune disorder meets main goal
* Key efficacy endpoint for analysis was survival. All 18
patients were alive after a median follow-up of 6.9 years at
data cut on 8th may 2014
Read more
patients were alive after a median follow-up of 6.9 years at
data cut on 8th may 2014
Read more
BRIEF-Hunan Er-kang Pharmaceutical receives patent license in Canada
* Says it received a patent license (No. 2872290), for a
hydroxypropyl starch hollow capsule and its manufacturing
method, in Canada
Read more
hydroxypropyl starch hollow capsule and its manufacturing
method, in Canada
Read more
BRIEF-Menicon to repurchase shares at 3.11 bln yen
* Says it to repurchase up to 1,000,100 shares, representing
a 5.46 percent stake, at the price of 3.07 billion yen in total,
from May 26 to July 31
Read more
a 5.46 percent stake, at the price of 3.07 billion yen in total,
from May 26 to July 31
Read more
BRIEF-Novartis CEO: Willing to sell Roche stake without premium
* Novartis CEO Joe Jimenez says no change in approach to
Roche stake, which is financial investment, will look at
opportuinities that arise
Read more
Roche stake, which is financial investment, will look at
opportuinities that arise
Read more
Tuesday, May 24, 2016
BRIEF-KYORIN Holdings unit to sign exclusive distribution agreement
* Says company MSD to grant subsidiary KYORIN Pharmaceutical
an exclusive distribution license for an allergic disease
treatment drug in Japan changed from joint marketing
Read more
an exclusive distribution license for an allergic disease
treatment drug in Japan changed from joint marketing
Read more
Swiss stocks - Factors to watch on May 25
ZURICH, May 25 (Reuters) - The following are some of the
main factors expected to affect Swiss stocks on Wednesday.
Read more
main factors expected to affect Swiss stocks on Wednesday.
Read more
BRIEF-Humanwell Healthcare Group unit acquires Pharma and RE Holdco
* Says its U.S. unit completes acquisition of Epic Pharma,
Epic RE Holdco for a combined $550 million
Read more
Epic RE Holdco for a combined $550 million
Read more
BRIEF-Pulike Biological Engineering says 2015 dividend payment date
* Says it will pay a cash dividend of 3 yuan (before tax)
per 10 shares and use additional paid-in capital to distribute
10 new share for every 10 shares, to shareholders of record on
May 30 for 2015
Read more
per 10 shares and use additional paid-in capital to distribute
10 new share for every 10 shares, to shareholders of record on
May 30 for 2015
Read more
BRIEF-Resverlogix explores potential of Apabetalone in phase 3 Betonmace clinical study
* Potential of Apabetalone for treatment of high-risk
diabetes and CKD is being explored in co's phase 3 Betonmace
clinical study
Read more
diabetes and CKD is being explored in co's phase 3 Betonmace
clinical study
Read more
BRIEF-Thunderbolt Pharma acquires rights to Dual Antagonist program from Astellas
* Thunderbolt Inc acquired all rights to Astellas BAFF/APRIL
Dual Antagonist program through an asset purchase agreement
Read more
Dual Antagonist program through an asset purchase agreement
Read more
UPDATE 1-SEC raises concerns about Valeant's use of "Non-GAAP" measures
May 24 (Reuters) - The Securities and Exchange Commission is
concerned about the way Canadian drugmaker Valeant
Pharmaceuticals International Inc has been disclosing
its "non-GAAP" financial measures, regulatory filings showed on
Tuesday.
Read more
concerned about the way Canadian drugmaker Valeant
Pharmaceuticals International Inc has been disclosing
its "non-GAAP" financial measures, regulatory filings showed on
Tuesday.
Read more
E-cigarette use rose rapidly in UK, France -European study
LONDON, May 24 (Reuters) - The number of people in France
and Britain who have tried an electronic or e-cigarette has
risen sharply in just two years, according to a Europe-wide
study published on Tuesday.
Read more
and Britain who have tried an electronic or e-cigarette has
risen sharply in just two years, according to a Europe-wide
study published on Tuesday.
Read more
BRIEF-Gilead Sciences appoints Kevin Young as COO
* Paul R. Carter, executive vice president, commercial
operations, has decided to depart Gilead
Read more
operations, has decided to depart Gilead
Read more
UPDATE 2-U.S. FDA panel recommends approval of Novo Nordisk diabetes drug
May 24 (Reuters) - A U.S. advisory panel on Tuesday
recommended approval of a new diabetes drug made by Novo Nordisk
A/S that combines two of its existing treatments in a
fixed-dose combination designed to be both effective and
convenient.
Read more
recommended approval of a new diabetes drug made by Novo Nordisk
A/S that combines two of its existing treatments in a
fixed-dose combination designed to be both effective and
convenient.
Read more
California AG sues Johnson & Johnson over marketing for pelvic mesh
NEW YORK, May 24 (Reuters) - California's attorney general
filed a lawsuit on Tuesday accusing Johnson & Johnson of
failing to warn doctors and patients about the severity and
frequency of complications associated with its pelvic mesh
devices.
Read more
filed a lawsuit on Tuesday accusing Johnson & Johnson of
failing to warn doctors and patients about the severity and
frequency of complications associated with its pelvic mesh
devices.
Read more
UPDATE 1-California AG sues Johnson & Johnson over marketing for pelvic mesh
NEW YORK, May 24 (Reuters) - California's attorney general
filed a lawsuit on Tuesday accusing Johnson & Johnson of
failing to warn doctors and patients about the severity and
frequency of complications associated with its pelvic mesh
devices.
Read more
filed a lawsuit on Tuesday accusing Johnson & Johnson of
failing to warn doctors and patients about the severity and
frequency of complications associated with its pelvic mesh
devices.
Read more
Britain's Serious Fraud Office re-examines funding model
LONDON, May 24 (Reuters) - The Serious Fraud Office (SFO),
Britain's leading fraud and corruption investigator and
prosecutor, said on Tuesday it was re-examining a funding model
that has been criticised for risking weakening investigations
and delaying cases.
Read more
Britain's leading fraud and corruption investigator and
prosecutor, said on Tuesday it was re-examining a funding model
that has been criticised for risking weakening investigations
and delaying cases.
Read more
Fitch Puts Bayer AG on Rating Watch Negative
(The following statement was released by the rating agency)
LONDON, May 24 (Fitch) Fitch Ratings has placed Bayer AG's
(Bayer) 'A' Long-Term
Issuer Default Rating (IDR) on Rating Watch Negative (RWN).
The rating action follows Bayer's announcement yesterday that it
intends to
launch a formal offer to acquire US-based chemical company
Monsanto Company
(A-/Stable) for USD62bn (approximately EUR55bn) including debt.
Should the
transaction go ahead at the conditions offered or with a revised
hig
Read more
LONDON, May 24 (Fitch) Fitch Ratings has placed Bayer AG's
(Bayer) 'A' Long-Term
Issuer Default Rating (IDR) on Rating Watch Negative (RWN).
The rating action follows Bayer's announcement yesterday that it
intends to
launch a formal offer to acquire US-based chemical company
Monsanto Company
(A-/Stable) for USD62bn (approximately EUR55bn) including debt.
Should the
transaction go ahead at the conditions offered or with a revised
hig
Read more
BRIEF-Epigenomics issues new shares by way of private placement
* Is raising around 6.8 million euros ($7.58 million) of
gross proceeds in a share capital increase
Read more
gross proceeds in a share capital increase
Read more
BRIEF-Elekta to pay 8.9 million euro in legal dispute
* An arbitration tribunal in London issued an award in a
dispute between two Elekta group companies and
humediQ GmbH
Read more
dispute between two Elekta group companies and
humediQ GmbH
Read more
BRIEF-Alteco Medical signs agreement with new distributor in Russia
* Says has signed agreement with Delrus on distribution of Alteco LPS Adsorber in parts of
Russia
Source text: http://bit.ly/1OTQZoC
Further company coverage:
Read more
Russia
Source text: http://bit.ly/1OTQZoC
Further company coverage:
Read more
Specialists call for gastric surgery to be standard diabetes treatment
LONDON, May 24 (Reuters) - Gastric surgery should be offered
as a standard treatment option for people with diabetes and
could help them control their condition for years without
medication, the world's leading diabetes organizations said on
Tuesday.
Read more
as a standard treatment option for people with diabetes and
could help them control their condition for years without
medication, the world's leading diabetes organizations said on
Tuesday.
Read more
Anthem CEO says Cigna deal moving forward with antitrust review
NEW YORK, May 24 (Reuters) - Anthem Inc Chief
Executive Officer Joseph Swedish on Tuesday said that the
antitrust process with Cigna Corp is moving forward as
expected - including on the national level - and that tensions
with the smaller insurer about the review are in the past.
Read more
Executive Officer Joseph Swedish on Tuesday said that the
antitrust process with Cigna Corp is moving forward as
expected - including on the national level - and that tensions
with the smaller insurer about the review are in the past.
Read more
India drugmaker Cipla profit falls short of forecast, down 69 pct
MUMBAI, May 24 (Reuters) - Cipla Ltd, India's
fifth-largest drugmaker by sales, reported a fall of 69 percent
in its quarterly earnings on Tuesday, far short of analysts'
forecasts.
Read more
fifth-largest drugmaker by sales, reported a fall of 69 percent
in its quarterly earnings on Tuesday, far short of analysts'
forecasts.
Read more
BRIEF-XBiotech to present positive preliminary survival data on Xilonix
* XBiotech to present positive preliminary survival data on
Xilonix at 18th European Society Of Medical Oncology's World
Congress On Gastrointestinal Cancer
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
Xilonix at 18th European Society Of Medical Oncology's World
Congress On Gastrointestinal Cancer
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
BRIEF-J&J says U.S. FDA expands indication of Invokamet
* U.S. FDA expands indication of Invokamet to include
first-line treatment of adults with type 2 diabetes
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
first-line treatment of adults with type 2 diabetes
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
BRIEF-Theratechnologies says 82.5 pct of patients achieved the primary endpoint in late-stage trial of HIV drug
* Notified by partner of results for primary end point of
phase iii trial with ibalizumab in patients with multi-drug
resistant hiv-1
Read more
phase iii trial with ibalizumab in patients with multi-drug
resistant hiv-1
Read more
BRIEF-Bristol-Myers Squibb says Health Canada approved Daklinza in combination with Sofosbuvir
* Myers squibb announces health canada's approval of
daklinza in combination with sofosbuvir
Read more
daklinza in combination with sofosbuvir
Read more
BRIEF-Interventional Spine Inc announces FDA clearance of Lordotic Opticage
* Announces FDA clearance of Lordotic Opticage
Source text for Eikon:
(Bengaluru Newsroom: +1 646 223 8780)
Read more
Source text for Eikon:
(Bengaluru Newsroom: +1 646 223 8780)
Read more
GSK lung drug succeeds in big UK study, after earlier miss
LONDON, May 24 (Reuters) - GlaxoSmithKline's new
inhaled medicine Breo proved significantly better than standard
care in a large British study that tested it in everyday use,
providing a fillip for the product after the failure of another
big trial in 2015.
Read more
inhaled medicine Breo proved significantly better than standard
care in a large British study that tested it in everyday use,
providing a fillip for the product after the failure of another
big trial in 2015.
Read more
UCB faces U.S. patent challenge for epilepsy drug
May 24 (Reuters) - The U.S. Patent and Trademark Office
(PTO) has begun a trial into whether Belgian pharmaceutical
company UCB's patent for an epilepsy drug is valid,
said a generic drug company that is challenging UCB's claim.
Read more
(PTO) has begun a trial into whether Belgian pharmaceutical
company UCB's patent for an epilepsy drug is valid,
said a generic drug company that is challenging UCB's claim.
Read more
South Africa's Ascendis Health buys two European firms, shares rise
JOHANNESBURG, May 24 (Reuters) - South Africa's Ascendis
Health Ltd said on Tuesday it bought two European
companies as part of its plan to expand globally and diversify
its pharmaceutical products, sending its shares higher.
Read more
Health Ltd said on Tuesday it bought two European
companies as part of its plan to expand globally and diversify
its pharmaceutical products, sending its shares higher.
Read more
BRIEF-iNtRON Biotechnology to raise 27.22 bln won via private placement
* Says it will issue 420,000 shares of preferred stock
through private placement, with par value of 500 won per share,
for debt-equity swap
Read more
through private placement, with par value of 500 won per share,
for debt-equity swap
Read more
Monday, May 23, 2016
BRIEF-Vectura & Propeller Health announce collaboration
* Vectura and propeller health announce collaboration to
develop digitally-connected inhalers to address chronic
respiratory diseases
Source text for Eikon:
Further company coverage:
Read more
develop digitally-connected inhalers to address chronic
respiratory diseases
Source text for Eikon:
Further company coverage:
Read more
BRIEF-Ascendis Health announces two acquisitions
* Acquisition of Remedica Holdings Limited and Scitec
International Societe A Responsabilite Limitee
Read more
International Societe A Responsabilite Limitee
Read more
BRIEF-Novartis: Sandoz' biosimilar rituximab regulatory submission accepted by European Medicines Agency
* Sandoz' biosimilar rituximab regulatory submission accepted by European Medicines Agency
Source text for Eikon:
Further company coverage:
(Gdynia Newsroom)
Read more
Source text for Eikon:
Further company coverage:
(Gdynia Newsroom)
Read more
BRIEF-Morphosys, MD Anderson to cooperate on oncology therapeutics
* Morphosys and md anderson cancer center join forces for
development of novel oncology therapeutics
Read more
development of novel oncology therapeutics
Read more
BRIEF-Wuhan Golden Laser plans to acquire advertising firm via cash, share issue
* Says it plans to acquire Shanghai advertising company for
700 million yuan ($106.82 million) via cash, share issue
Read more
700 million yuan ($106.82 million) via cash, share issue
Read more
BRIEF-Kangmei Pharmaceutical says 2015 dividend payment date
* Says it will pay cash dividend of 7.5 yuan per 10
preferred shares (before tax) to shareholders for 2015 as a
record of May 27
Read more
preferred shares (before tax) to shareholders for 2015 as a
record of May 27
Read more
BRIEF-Sinocare to invest 551.3 mln yuan to set up unit
* Says company will invest 551.3 million yuan to establish a
unit based in Changsha with registered capital of 20 million
yuan, with an investment firm
Read more
unit based in Changsha with registered capital of 20 million
yuan, with an investment firm
Read more
BRIEF-StemCells Inc files for rights offering for up to $30 mln
* Files for rights offering for up to $30 million - SEC
filing
Source text for Eikon:
Further company coverage:
Read more
filing
Source text for Eikon:
Further company coverage:
Read more
BRIEF-Allergan's botox wins Japanese approval to treat crow's feet lines
* Allergan's botox vista (botulinum toxin type a) receives
national marketing authorisation in japan for treatment of
crow's feet lines in adult patients
Read more
national marketing authorisation in japan for treatment of
crow's feet lines in adult patients
Read more
BRIEF-Wright Medical Group announces secondary offering by selling shareholder
* Wright medical group n.v. Announces secondary offering of
6.2 million ordinary shares by selling shareholder
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom +1-646-223-8780)
Read more
6.2 million ordinary shares by selling shareholder
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom +1-646-223-8780)
Read more
BRIEF-Biostar Pharma Q1 sales fall 88.4 pct to $800,000
* Biostar Pharmaceuticals, Inc. Announces its quarterly
results for three months ended march 31, 2016
Read more
results for three months ended march 31, 2016
Read more
Doubts mount over merger of health insurers Anthem, Cigna
May 23 (Reuters) - Wall Street expressed growing doubts
about a pending $54 billion merger of U.S. health insurers
Anthem Inc and Cigna Corp on Monday as news of
management squabbles added to concerns over its review by
antitrust regulators.
Read more
about a pending $54 billion merger of U.S. health insurers
Anthem Inc and Cigna Corp on Monday as news of
management squabbles added to concerns over its review by
antitrust regulators.
Read more
BRIEF-Ipsen SA says Exelixis Inc reported positive top-line results from Cabosun phase 2 trial of Cabozantinib
* reported positive top line results from Cabosun phase 2
trial of Cabozantinib in patients with untreated advanced renal
cell carcinoma
Read more
trial of Cabozantinib in patients with untreated advanced renal
cell carcinoma
Read more
UPDATE 1-Allergan CEO says company is "weeks away" from closing Teva deal
NEW YORK, May 23 (Reuters) - Allergan Plc Chief
Executive Brent Saunders said on Monday the company expects to
close the $40.5 billion sale of its generic medicines portfolio
to Teva Pharmaceutical Industries Ltd in a matter of
weeks, opening the door for new acquisitions.
Read more
Executive Brent Saunders said on Monday the company expects to
close the $40.5 billion sale of its generic medicines portfolio
to Teva Pharmaceutical Industries Ltd in a matter of
weeks, opening the door for new acquisitions.
Read more
Allergan CEO says company is "weeks away" from closing Teva deal
May 23 (Reuters) - Allergan Inc Chief Executive
Brent Saunders said on Monday the company expects to close the
$40.5 billion sale of its generic medicines portfolio to Teva
Pharmaceutical Industries Ltd in a matter of weeks,
opening the door for new acquisitions.
Read more
Brent Saunders said on Monday the company expects to close the
$40.5 billion sale of its generic medicines portfolio to Teva
Pharmaceutical Industries Ltd in a matter of weeks,
opening the door for new acquisitions.
Read more
BRIEF-Digital Bros to launch Terraria in Greater China with iDreamSky
* Assigns via its unit 505 Games exclusive rights to iDreamSky Technology Limited
to launch the mobile version (Android, iOS and Windows) of Terraria in Greater China
Read more
to launch the mobile version (Android, iOS and Windows) of Terraria in Greater China
Read more
UK drugs watchdog warns it will struggle if Britain leaves EU
LONDON, May 23 (Reuters) - A British vote to leave the
European Union would disrupt and could well delay the approval
of new drugs, leaving UK regulators struggling to cope, the
chairman of the country's medicines watchdog said on Monday.
Read more
European Union would disrupt and could well delay the approval
of new drugs, leaving UK regulators struggling to cope, the
chairman of the country's medicines watchdog said on Monday.
Read more
UPDATE 1-Valeant CEO Papa plans to lower debt by more than $1.5 bln in 2016
NEW YORK, May 23 (Reuters) - Valeant Pharmaceuticals Inc
plans to lower its debt by at least $1.5 billion this
year, Chief Executive Officer Joseph Papa said on Monday during
his first large meeting with investors since taking the top job
three weeks ago.
Read more
plans to lower its debt by at least $1.5 billion this
year, Chief Executive Officer Joseph Papa said on Monday during
his first large meeting with investors since taking the top job
three weeks ago.
Read more
BRIEF-Coherus Biosciences prices public offering of common stock
* Coherus prices public offering of common stock
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
UPDATE 1-FDA staff question utility of Sanofi diabetes drugs
May 23 (Reuters) - A preliminary review by the U.S. Food and
Drug Administration questioned whether Sanofi SA's
experimental diabetes drug lixisenatide contributed any benefit
to a fixed-dose combination product the company hopes to market.
Read more
Drug Administration questioned whether Sanofi SA's
experimental diabetes drug lixisenatide contributed any benefit
to a fixed-dose combination product the company hopes to market.
Read more
BRIEF-Chemocentryx says treatment with CCX168 successful in achieving clinical efficacy endpoints
* Chemocentryx announces presentation of positive results
from Phase II ANCA-associated vasculitis clear trial of orally
administered complement 5a receptor inhibitor CCX168 at the 53rd
ERA-EDTA congress
Read more
from Phase II ANCA-associated vasculitis clear trial of orally
administered complement 5a receptor inhibitor CCX168 at the 53rd
ERA-EDTA congress
Read more
Deals of the day- Mergers and acquisitions
May 23 (Reuters) - The following bids, mergers, acquisitions
and disposals were reported by 1300 GMT on Monday:
Read more
and disposals were reported by 1300 GMT on Monday:
Read more
BRIEF-Cryoport to provide logistics support for early stage trial
* Cryoport to provide cold chain logistics support for
International Stem Cell Corporation's Phase I clinical trial for
the treatment of Parkinson's disease
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1 646 223 8780)
Read more
International Stem Cell Corporation's Phase I clinical trial for
the treatment of Parkinson's disease
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1 646 223 8780)
Read more
BRIEF-Xenoport says merger agreement contains termination fee of $16.5 mln
* Merger agreement contains termination provisions subject,
in certain circumstances, to payment of termination fee of $16.5
million - sec filing
Read more
in certain circumstances, to payment of termination fee of $16.5
million - sec filing
Read more
BRIEF-Chengdu Huasun in deal to buy pharma firm stake, share trade to resume on May 24
* Says it signs framework agreement to buy 51 percent stake
in pharma firm in Sichuan province by cash
Read more
in pharma firm in Sichuan province by cash
Read more
BRIEF-Egalet settles patent litigations with Purdue Pharma
* Settlement relates to alleged patent infringements against
Egalet and product licensor Acura Pharmaceuticals for Oxaydo
Tablets CII
Read more
Egalet and product licensor Acura Pharmaceuticals for Oxaydo
Tablets CII
Read more
BRIEF-OncoSec announces $10 mln at-the-market registered direct offering
* Agreed to sell an aggregate of 5.5 million shares of
common stock, or pre-funded warrants in lieu thereof, at price
of $1.815/share
Read more
common stock, or pre-funded warrants in lieu thereof, at price
of $1.815/share
Read more
European shares buoyed by tech, pharma stocks; Fiat, Bayer slump
* Aixtron rallies as takeover bid agreed
(ADVISORY- Reuters plans to replace intra-day European and UK
stock market reports with a Live Markets blog on Eikon (see cpurl://apps.cp./cms/?pageId=livemarkets
for site in development). Adds details, share prices)
Read more
(ADVISORY- Reuters plans to replace intra-day European and UK
stock market reports with a Live Markets blog on Eikon (see cpurl://apps.cp./cms/?pageId=livemarkets
for site in development). Adds details, share prices)
Read more
BRIEF-Innopharmax gets patent for Gemcitabine Oral in Australia
* Says it got patent named Self Micro-Emulsifying Oral
Pharmaceutical Composition of Hydrophilic Drug and Preparation
Method Thereof for Gemcitabine Oral in Australia
Read more
Pharmaceutical Composition of Hydrophilic Drug and Preparation
Method Thereof for Gemcitabine Oral in Australia
Read more
BRIEF-Bioton units to sell 29.29 pct stake in INDAR ZAO
* Said on Friday that its units Mindar Holdings Ltd and
Germonta Holdings Ltd signed a conditional agreement to sell all
their 29.29 pct stake in INDAR ZAO to Luraq Investments Ltd
Read more
Germonta Holdings Ltd signed a conditional agreement to sell all
their 29.29 pct stake in INDAR ZAO to Luraq Investments Ltd
Read more
BRIEF-Tianjin Lisheng Pharmaceutical to pay 2015 dividend on May 30
* Says it will pay cash dividend of 4.00 yuan per 10 shares
(before tax) to shareholders of record on May 27, for 2015
Read more
(before tax) to shareholders of record on May 27, for 2015
Read more
Iraq bans import of poultry products from Italy, Missouri
BAGHDAD, May 23 (Reuters) - Iraq has extended a ban on live
and frozen poultry product imports to include Italy and the U.S.
state of Missouri due to concerns over bird flu, a government
statement said on Monday.
Read more
and frozen poultry product imports to include Italy and the U.S.
state of Missouri due to concerns over bird flu, a government
statement said on Monday.
Read more
Sunday, May 22, 2016
Swiss stocks - Factors to watch on May 23
ZURICH, May 23 (Reuters) - The following are some of the
main factors expected to affect Swiss stocks on Monday:
Read more
main factors expected to affect Swiss stocks on Monday:
Read more
German stocks - Factors to watch on May 23
FRANKFURT, May 23 (Reuters) - The following are some of the
factors that may move German stocks on Monday:
Read more
factors that may move German stocks on Monday:
Read more
BRIEF-Dirui Industrial to acquire 6.6 pct stake in biotech firm
* Says it will acquire 6.6 percent stake (2.2 million
shares) in a Xiamen-based biotech firm, for business
diversification
Read more
shares) in a Xiamen-based biotech firm, for business
diversification
Read more
HK Exchange says 15 firms buy back shares
HONG KONG, May 23 (Reuters) - The Hong Kong stock exchange said on Monday 15
companies had repurchased their ordinary shares in the market.
The following is a table regarding share buybacks:
Company name Date of No. of Highest Lowest
(Stock code) Repurchase Securities Price per Price per
Repurchased share share
BILLION IND 2016/05/20 22,000 HK$4.88 HK$4.82
Read more
companies had repurchased their ordinary shares in the market.
The following is a table regarding share buybacks:
Company name Date of No. of Highest Lowest
(Stock code) Repurchase Securities Price per Price per
Repurchased share share
BILLION IND 2016/05/20 22,000 HK$4.88 HK$4.82
Read more
Australia & NZ shares ease, weakness in iron ore hits miners
SYDNEY/WELLINGTON, May 23 (Reuters) - Australian shares fell
to their lowest in nearly two weeks on Monday as weakness in
iron ore prices weighed on the major miners, while a soggy
performance by the big banks all but ensured a negative start to
the week.
Read more
to their lowest in nearly two weeks on Monday as weakness in
iron ore prices weighed on the major miners, while a soggy
performance by the big banks all but ensured a negative start to
the week.
Read more
UPDATE 1-Stada counters activist investor's board move with its own candidates
* Active Ownership says expects entire board to be newly
elected
(Adds statement from Active Ownership, paragraphs 5-7)
Read more
elected
(Adds statement from Active Ownership, paragraphs 5-7)
Read more
China's drugs watchdog struggles as senior staff lured away by industry
SHANGHAI, May 23 (Reuters) - Promises of higher salaries and
greater freedom at work are luring officials from China's
high-profile drugs watchdog to the companies they had regulated,
a blow just as the country looks to tighten oversight and drive
innovation.
Read more
greater freedom at work are luring officials from China's
high-profile drugs watchdog to the companies they had regulated,
a blow just as the country looks to tighten oversight and drive
innovation.
Read more
UPDATE 1-Anthem, Cigna merger squabbles could delay antitrust approval -WSJ
WASHINGTON, May 22 (Reuters) - Quarrels have broken out
behind the scenes of Anthem Inc's proposed acquisition
of Cigna Corp, as the health insurers seek regulatory
approval for their landmark deal, the Wall Street Journal
reported on Sunday.
Read more
behind the scenes of Anthem Inc's proposed acquisition
of Cigna Corp, as the health insurers seek regulatory
approval for their landmark deal, the Wall Street Journal
reported on Sunday.
Read more
Inquiry points to maker and lab in fatal French drug trial-reports
PARIS, May 22 (Reuters) - An official investigation into a
clinical drug trial that left one person dead and five others
hospitalised in France in January pointed to both the laboratory
and the maker for committing errors in the testing process, two
dailies said.
Read more
clinical drug trial that left one person dead and five others
hospitalised in France in January pointed to both the laboratory
and the maker for committing errors in the testing process, two
dailies said.
Read more
Stada counters activist investor's board move with own candidates
FRANKFURT, May 22 (Reuters) - German generic drugmaker Stada
said on Sunday it would propose three new independent
directors to join its supervisory board, countering nominations
from investor Active Ownership.
Read more
said on Sunday it would propose three new independent
directors to join its supervisory board, countering nominations
from investor Active Ownership.
Read more
Anthem, Cigna merger squabbles could delay antitrust approval - WSJ
WASHINGTON, May 22 (Reuters) - Quarrels have broken out
behind the scenes of Anthem Inc's proposed acquisition
of Cigna Corp, as the health insurers seek regulatory
approval for their landmark deal, the Wall Street Journal
reported on Sunday.
Read more
behind the scenes of Anthem Inc's proposed acquisition
of Cigna Corp, as the health insurers seek regulatory
approval for their landmark deal, the Wall Street Journal
reported on Sunday.
Read more
EXPERT VIEWS-What are the main humanitarian needs of Boko Haram victims in Niger?
DIFFA, Niger, May 22 (Thomson Reuters Foundation) - Almost a
quarter-of-a-million people are living in makeshift camps in
Niger's southeast Diffa region, where Nigerians and Nigeriens
alike have been uprooted by Boko Haram violence.
Read more
quarter-of-a-million people are living in makeshift camps in
Niger's southeast Diffa region, where Nigerians and Nigeriens
alike have been uprooted by Boko Haram violence.
Read more
UPDATE 2-Struggling Novartis heart drug boosted by new medical guidelines
* Amgen's Corlanor also added to guideline list
(Adds comment from Novartis chief medical officer)
Read more
(Adds comment from Novartis chief medical officer)
Read more
Saturday, May 21, 2016
Costa Rica confirms microcephaly birth, possible Zika link
SAN JOSE, May 20 (Reuters) - A Salvadoran woman suspected of
being infected with the Zika virus has given birth in Costa Rica
to a baby girl that tested positive for microcephaly, a rare
birth defect, authorities said on Friday.
Read more
being infected with the Zika virus has given birth in Costa Rica
to a baby girl that tested positive for microcephaly, a rare
birth defect, authorities said on Friday.
Read more
Friday, May 20, 2016
CORRECTED-Wrist-band device for alcohol monitoring wins U.S. prize
SAN FRANCISCO, May 20 (Reuters) - A San Francisco-based
company has won a U.S. government-sponsored competition with an
alcohol monitoring devices that can be worn on the wrist, the
latest milestone in the development of wearable technologies
that monitor and diagnose medical conditions.
Read more
company has won a U.S. government-sponsored competition with an
alcohol monitoring devices that can be worn on the wrist, the
latest milestone in the development of wearable technologies
that monitor and diagnose medical conditions.
Read more
BRIEF-Ascendis Pharma A/S files for potential share offering of up to $250 mln
* Ascendis Pharma A/S files for potential share offering of
up to $250 million - SEC filing
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1 646 223 8780)
Read more
up to $250 million - SEC filing
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1 646 223 8780)
Read more
BRIEF-Cogentix medical adjourns May 20, 2016 annual meeting in response to court ruling
* Cogentix medical adjourns may 20, 2016 annual meeting in response to court
ruling; adjourned meeting date set for May 24, 2016 at 12:00 p.m. Ct
Read more
ruling; adjourned meeting date set for May 24, 2016 at 12:00 p.m. Ct
Read more
UPDATE 4-Mexico to extradite drug boss Guzman to U.S., won't face death penalty
MEXICO CITY, May 20 (Reuters) - Mexico approved the
extradition of drug lord Joaquin "El Chapo" Guzman to the United
States on Friday after receiving guarantees he would not face
the death penalty, and the kinkgpin's lawyers vowed to block the
move.
Read more
extradition of drug lord Joaquin "El Chapo" Guzman to the United
States on Friday after receiving guarantees he would not face
the death penalty, and the kinkgpin's lawyers vowed to block the
move.
Read more
New medical guidelines back use of Novartis heart failure drug
LONDON, May 20 (Reuters) - New global guidelines on the
treatment of heart failure endorse the use of Novartis'
Entresto, boosting the prospects for a drug that has struggled
to gain traction since its launch last year.
Read more
treatment of heart failure endorse the use of Novartis'
Entresto, boosting the prospects for a drug that has struggled
to gain traction since its launch last year.
Read more
BRIEF-Valeant says Brian Stolz resigned as senior VP neurology, dentistry & generics
* Brian M. Stolz tendered his resignation as senior vice
president neurology, dentistry and generics
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
president neurology, dentistry and generics
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
BRIEF-Empery Asset Management reports 5.53 pct stake in Biostage
* Empery Asset Management, Lp reports 5.53% stake in
Biostage as of May 15, 2016 - SEC filing Source text for Eikon:
Read more
Biostage as of May 15, 2016 - SEC filing Source text for Eikon:
Read more
Thai king treated for 'water on the brain' - palace
BANGKOK, May 20 (Reuters) - Thailand's 88-year-old King
Bhumibol Adulyadej has received treatment for 'water on the
brain', the Royal Household Bureau said in a statement on
Friday.
Read more
Bhumibol Adulyadej has received treatment for 'water on the
brain', the Royal Household Bureau said in a statement on
Friday.
Read more
CORRECTED-UPDATE 1-U.S. CDC says 157 pregnant women in U.S. infected with Zika
May 20 (Reuters) - Some 157 pregnant women in the United States and another 122 in U.S. territories, primarily Puerto Rico, have tested positive for infection with the Zika virus, the U.S. Centers for Disease Control and Prevention said on Friday.
Read more
Read more
UPDATE 2-U.S. CDC says 157 pregnant women in U.S. infected with Zika
May 20 (Reuters) - Some 157 pregnant women in the United States and another 122 in U.S. territories, primarily Puerto Rico, have tested positive for infection with the Zika virus, the U.S. Centers for Disease Control and Prevention said on Friday.
Read more
Read more
RPT-Pelvic mesh maker AMS claims women were lured into needless surgeries
May 20 (Reuters) - American Medical Systems, a major
defendant in litigation over controversial vaginal mesh
devices, is accusing "a pyramid of businessmen, doctors and
lawyers" of luring women into unwarranted surgeries to remove
the implants and inflate their damages claims.
Read more
defendant in litigation over controversial vaginal mesh
devices, is accusing "a pyramid of businessmen, doctors and
lawyers" of luring women into unwarranted surgeries to remove
the implants and inflate their damages claims.
Read more
UPDATE 1-FDA to modify food label guidelines to include added sugar details
May 20 (Reuters) - The U.S. Food and Drug Administration
said it would update guidelines for nutritional labels on
packaged food and beverages to include information on added
sugar and to prominently display calorie count and servings.
Read more
said it would update guidelines for nutritional labels on
packaged food and beverages to include information on added
sugar and to prominently display calorie count and servings.
Read more
RPT-FDA to modify nutrition label guidelines for packaged food, drinks
May 20 (Reuters) - The U.S. Food and Drug Administration
will modify guidelines for nutritional labels on packaged food
and beverages to prominently display calorie count and servings,
the regulator said.
Read more
will modify guidelines for nutritional labels on packaged food
and beverages to prominently display calorie count and servings,
the regulator said.
Read more
BRIEF-FDA modernizes nutrition facts label for packaged foods
* New nutrition facts label will include updated design to
highlight "calories" and "servings," two important elements for
informed food choices
Read more
highlight "calories" and "servings," two important elements for
informed food choices
Read more
UPDATE 1-FDA staff question utility, trials of Novo Nordisk diabetes drug
May 20 (Reuters) - A preliminary review by the U.S. Food and
Drug Administration of Novo Nordisk A/S's experimental
diabetes drug, IDegLira, questioned the interpretability of the
study findings and practical utility of the treatment, according
to a review posted on the agency's website on Friday.
Read more
Drug Administration of Novo Nordisk A/S's experimental
diabetes drug, IDegLira, questioned the interpretability of the
study findings and practical utility of the treatment, according
to a review posted on the agency's website on Friday.
Read more
BRIEF-Pfizer says EMA acceptance for Trumenba marketing authorization application review
* Pfizer announces European Medicines Agency acceptance for
review of marketing authorization application for Trumenba
(Meningococcal Group B Vaccine)
Source text for Eikon:
Further company coverage:
Read more
review of marketing authorization application for Trumenba
(Meningococcal Group B Vaccine)
Source text for Eikon:
Further company coverage:
Read more
BRIEF-Biostage Director Thomas Robinson reports open market purchase
* Director Thomas Robinson reports open market purchase of
18,000 shares of co's common stock on May 19 at average price of
$1.35 each - sec filing
Source text - (http://1.usa.gov/1NBLhHT)
Further company coverage:
Read more
18,000 shares of co's common stock on May 19 at average price of
$1.35 each - sec filing
Source text - (http://1.usa.gov/1NBLhHT)
Further company coverage:
Read more
China slashes GSK, AstraZeneca drug prices in cost-cutting drive
SHANGHAI/LONDON, May 20 (Reuters) - Chinese health
authorities announced price cuts of up to two-thirds for three
expensive drugs on Friday in the latest move to reduce the cost
of healthcare for patients in the world's second-biggest
economy.
Read more
authorities announced price cuts of up to two-thirds for three
expensive drugs on Friday in the latest move to reduce the cost
of healthcare for patients in the world's second-biggest
economy.
Read more
BRIEF-AmCad BioMed to issue new shares at T$30 per share
* Says 10 percent of the new shares to be offered to the
company's employees, 10 percent of the new shares to be offered
through public offering, remaining 80 pct to be offered to the
existing shareholders, who are eligible to purchase 230.97626
shares for every 1,000 shares they hold
Read more
company's employees, 10 percent of the new shares to be offered
through public offering, remaining 80 pct to be offered to the
existing shareholders, who are eligible to purchase 230.97626
shares for every 1,000 shares they hold
Read more
BRIEF-Immunicum Q3 2015/16 operating loss narrows to SEK 9.5 million
* Q3 2015/16 operating loss 9.5 million Swedish crowns ($1.14 million) versus loss 10.7
million crowns
Read more
million crowns
Read more
Thursday, May 19, 2016
Swiss stocks - Factors to watch on May 20
ZURICH, May 20 (Reuters) - The following are some of the
main factors expected to affect Swiss stocks on May 20:
Read more
main factors expected to affect Swiss stocks on May 20:
Read more
BRIEF-Ypsomed Holding FY net profit up at 35.8 mln Swiss francs
* FY consolidated sales totaling 336.9 million Swiss francs
($339.82 million) (prior year: 306.6 million Swiss francs)
Read more
($339.82 million) (prior year: 306.6 million Swiss francs)
Read more
PRESS DIGEST - Wall Street Journal - May 20
May 20 (Reuters) - The following are the top stories in the
Wall Street Journal. Reuters has not verified these stories and
does not vouch for their accuracy.
Read more
Wall Street Journal. Reuters has not verified these stories and
does not vouch for their accuracy.
Read more
BRIEF-Hainan Honz Pharmaceutical receives patent license
* Says it receives a patent license (No. ZL 2013 1
0492329.X), for a kind of Chinese traditional medicine bitter
taste mask
Read more
0492329.X), for a kind of Chinese traditional medicine bitter
taste mask
Read more
Australia shares rebound, set for weekly gain; NZ more subdued
SYDNEY/WELLINGTON, May 20 (Reuters) - Australian shares
staged a modest rebound on Friday after two sessions of declines
led by gains in the mining sector and some of the major banks,
setting the market on track to end the week a touch higher.
Read more
staged a modest rebound on Friday after two sessions of declines
led by gains in the mining sector and some of the major banks,
setting the market on track to end the week a touch higher.
Read more
Rush for ag-chem megadeals clogs regulatory path, worries farmers
WASHINGTON/CHICAGO, May 19 (Reuters) - As Bayer AG
joins the agricultural sector's scramble to
consolidate, its bid for Monsanto Co may be a tipping
point for U.S. farmers, federal lawmakers and regulators
concerned the tie-ups may harm the farm economy.
Read more
joins the agricultural sector's scramble to
consolidate, its bid for Monsanto Co may be a tipping
point for U.S. farmers, federal lawmakers and regulators
concerned the tie-ups may harm the farm economy.
Read more
BRIEF-Hybio Pharmaceutical receives patent license
* Says it receives a patent license (No. ZL 2012 1
0571693.0), for nanoparticle and preparation method thereof
Read more
0571693.0), for nanoparticle and preparation method thereof
Read more
BRIEF-Neovasc says jury found in favor of CardiAQ on relief for contract breach
* Jury found in favor of CardiAQ, on claims for relief for
breach of contract, breach of duty of honesty in contractual
performance
Read more
breach of contract, breach of duty of honesty in contractual
performance
Read more
Elderly Floridian cannot afford medicine, kills suffering wife
May 19 (Reuters) - An elderly Florida man was in jail on
Thursday after he said he fatally shot his ailing wife because
her medications were no longer affordable and she was in pain.
Read more
Thursday after he said he fatally shot his ailing wife because
her medications were no longer affordable and she was in pain.
Read more
UPDATE 1-Valeant gets notice of default from bondholders
May 19 (Reuters) - Beleaguered Canadian drugmaker Valeant
Pharmaceuticals International Inc said it
received a notice of default from bondholders for the delay in
filing its first-quarter report.
Read more
Pharmaceuticals International Inc said it
received a notice of default from bondholders for the delay in
filing its first-quarter report.
Read more
Roche breast cancer drug Perjeta rejected by UK cost agency
LONDON, May 20 (Reuters) - Roche's breast cancer
drug Perjeta, or pertuzumab, has been turned down for use on
Britain's state health service, making it the latest in a number
of pricey new cancer treatments deemed not to offer value for
money.
Read more
drug Perjeta, or pertuzumab, has been turned down for use on
Britain's state health service, making it the latest in a number
of pricey new cancer treatments deemed not to offer value for
money.
Read more
UPDATE 2-U.S. Senate approves $1.1 billion to fight Zika virus
WASHINGTON, May 19 (Reuters) - An election-year fight over
addressing the spreading Zika virus intensified in the U.S.
Congress as the Senate on Thursday approved $1.1 billion in
emergency money one day after the House of Representatives voted
$622.1 million financed through cuts to existing programs.
Read more
addressing the spreading Zika virus intensified in the U.S.
Congress as the Senate on Thursday approved $1.1 billion in
emergency money one day after the House of Representatives voted
$622.1 million financed through cuts to existing programs.
Read more
BRIEF-Seres Therapeutics CEO reports acquisition of 160,965 shares of co by exercise of options - SEC filing
* Seres Therapeutics CEO Roger Pomerantz reports acquisition
of 160,965 shares of co by exercise of options on May 18, at
price of $0.71 - SEC filing
Source text (http://bit.ly/1NAOQhm)
Further company coverage:
Read more
of 160,965 shares of co by exercise of options on May 18, at
price of $0.71 - SEC filing
Source text (http://bit.ly/1NAOQhm)
Further company coverage:
Read more
BRIEF-Aegerion Pharmaceuticals files for $100 mln mixed shelf offering
* Aegerion Pharmaceuticals Inc files for $100 mln mixed
shelf offering - SEC FILING
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1 646 223 8780)
Read more
shelf offering - SEC FILING
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1 646 223 8780)
Read more
UPDATE 1-Yellow fever outbreaks in Africa need action, mass vaccination - WHO
GENEVA, May 19 (Reuters) - Outbreaks of deadly yellow fever
in Angola and the Democratic Republic of Congo do not constitute
a global health emergency but require stepped-up control
measures and mass vaccination, the World Health Organisation
(WHO) said on Thursday.
Read more
in Angola and the Democratic Republic of Congo do not constitute
a global health emergency but require stepped-up control
measures and mass vaccination, the World Health Organisation
(WHO) said on Thursday.
Read more
UPDATE 2-Golfer Mickelson not charged in insider trading case, will pay back $1 mln
NEW YORK, May 19 (Reuters) - Late in July 2012, Phil Mickelson, one of the world's most famous golfers, received a phone call from a well-known professional sports gambler, William "Billy" Walters.
Read more
Read more
Canada approves GMO salmon as food, livestock feed
OTTAWA, May 19 (Reuters) - Canadian health officials said on
Thursday they have approved a type of genetically modified
salmon as safe to eat, clearing the way for it to be sold in the
country.
Read more
Thursday they have approved a type of genetically modified
salmon as safe to eat, clearing the way for it to be sold in the
country.
Read more
UPDATE 1-Oklahoma bill to jail abortion doctors heads to governor
OKLAHOMA CITY, May 19 (Reuters) - An Oklahoma bill that
could send any doctor who performs an abortion to jail headed to
the governor on Thursday, with opponents saying the measure is
unconstitutional and promising a legal battle against the
cash-strapped state if it is approved.
Read more
could send any doctor who performs an abortion to jail headed to
the governor on Thursday, with opponents saying the measure is
unconstitutional and promising a legal battle against the
cash-strapped state if it is approved.
Read more
BRIEF-Medtech announces first ROSA spine surgery in Spain
* Announces first ROSA spine surgery in Spain
Source text: http://bit.ly/1TJg5CP
Further company coverage:
(Gdynia Newsroom)
Read more
Source text: http://bit.ly/1TJg5CP
Further company coverage:
(Gdynia Newsroom)
Read more
U.S. Senate approves $1.1 billion to fight Zika virus
WASHINGTON, May 19 (Reuters) - An election-year fight over
addressing the spreading Zika virus intensified in the U.S.
Congress as the Senate on Thursday approved $1.1 billion in
emergency money one day after the House of Representatives voted
$622.1 million financed through cuts to existing programs.
Read more
addressing the spreading Zika virus intensified in the U.S.
Congress as the Senate on Thursday approved $1.1 billion in
emergency money one day after the House of Representatives voted
$622.1 million financed through cuts to existing programs.
Read more
BRIEF-Qiagen extends tender offer period for acquisition of Exiqon A/S
* Extends tender offer period for acquisition of Exiqon A/S
offer for DKK 18 per share remains valid until 2 june 2016
Read more
offer for DKK 18 per share remains valid until 2 june 2016
Read more
BRIEF-MedicPen rights issue oversubscribed
* Rights issue was subscribed to about 19.6 million Swedish crowns ($2.35 million),
equivalent to 168 pct
Read more
equivalent to 168 pct
Read more
BRIEF-Anika Therapeutics announces Canadian launch of cingal
* Announces Canadian launch of cingal for the treatment of
pain associated with osteoarthritis of the knee
Read more
pain associated with osteoarthritis of the knee
Read more
Novartis launches new Entresto trials in bid to boost sales
ZURICH, May 19 (Reuters) - Novartis's heart failure
drug Entresto will be subjected to a battery of new trials as
the Swiss drugmaker seeks to boost the medicine after a
disappointing introduction.
Read more
drug Entresto will be subjected to a battery of new trials as
the Swiss drugmaker seeks to boost the medicine after a
disappointing introduction.
Read more
BRIEF-Rosetta Genomics Q1 non-gaap loss per share $0.18 excluding items
* Company's current operations and plans include a
cost-reduction plan should it be unable to raise sufficient
additional capital
Read more
cost-reduction plan should it be unable to raise sufficient
additional capital
Read more
BRIEF-Covalon sees products cleared in 8 countries by 2016 end
* Expects to have its products cleared in Mexico, Colombia,
Peru, Venezuela, Ecuador, Dominican Republic, Paraguay And
Uruguay by end of 2016
Read more
Peru, Venezuela, Ecuador, Dominican Republic, Paraguay And
Uruguay by end of 2016
Read more
Cigna plans to cut opioid use among U.S. customers by 25 pct
NEW YORK, May 19 (Reuters) - Health insurer Cigna Corp
plans to cut its customers' prescriptions for opioid
treatments by 25 percent over the next three years, putting its
weight behind a U.S. government battle against addictive
painkillers.
Read more
plans to cut its customers' prescriptions for opioid
treatments by 25 percent over the next three years, putting its
weight behind a U.S. government battle against addictive
painkillers.
Read more
BRIEF-Genmab to present daratumumab data at June conference
* Says data on daratumumab and ofatumumab will be presented
at
European Hematology Association's (EHA) congress in Copenhagen,
June 9-12
Read more
at
European Hematology Association's (EHA) congress in Copenhagen,
June 9-12
Read more
BRIEF-Check-Cap reports Q1 loss per share $0.21
* Qtrly loss per share $0.21
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1 646 223 8780)
Read more
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1 646 223 8780)
Read more
BRIEF-Synmosa Biopharma adjusts 2015 dividend payment
* Says it adjusts to use additional paid-in capital to
distribute 100 shares for every 1,000 shares from 80 shares for
every 1,000 shares as stock dividend
Read more
distribute 100 shares for every 1,000 shares from 80 shares for
every 1,000 shares as stock dividend
Read more
U.N.'s rights chief urges firms to follow Pfizer's lead on death penalty
GENEVA, May 19 (Reuters) - U.N. High Commissioner for Human
Rights Zeid Ra'ad al Hussein praised Pfizer on Thursday for
banning sales of its chemicals that have been used for lethal
injections in some U.S. states, and urged other companies to
follow its lead.
Read more
Rights Zeid Ra'ad al Hussein praised Pfizer on Thursday for
banning sales of its chemicals that have been used for lethal
injections in some U.S. states, and urged other companies to
follow its lead.
Read more
India's Lupin Q4 profit up 48 pct, beats estimates
MUMBAI, May 19 (Reuters) - Lupin Ltd, India's
third-largest drugmaker, reported a 48 percent rise in quarterly
net profit, outpacing analysts' estimates mainly due to higher
drug sales in its largest market, the United States.
Read more
third-largest drugmaker, reported a 48 percent rise in quarterly
net profit, outpacing analysts' estimates mainly due to higher
drug sales in its largest market, the United States.
Read more
BRIEF-Merck KGaA expects to file for first approval of Avelumab in H2
* CEO says expects to file for first approval of Avelumab in
merkel cell carcinoma in H2
Further company coverage:
Read more
merkel cell carcinoma in H2
Further company coverage:
Read more
BRIEF-CHONGKUNDANG HOLDINGS to raise 55.7 bln won via public offering
* Says it will issue 620,740 shares of common stock with par
value of 2,500 won per share in public offering
Read more
value of 2,500 won per share in public offering
Read more
PRESS DIGEST - Wall Street Journal - May 19
May 19 (Reuters) - The following are the top stories in the
Wall Street Journal. Reuters has not verified these stories and
does not vouch for their accuracy.
Read more
Wall Street Journal. Reuters has not verified these stories and
does not vouch for their accuracy.
Read more
Wednesday, May 18, 2016
Swiss stocks - Factors to watch on May 19
ZURICH, May 19 (Reuters) - The following are some of the
main factors expected to affect Swiss stocks on Thursday.
Read more
main factors expected to affect Swiss stocks on Thursday.
Read more
German stocks - Factors to watch on May 19
FRANKFURT, May 19 (Reuters) - The following are some of the
factors that may move German stocks on Thursday:
Read more
factors that may move German stocks on Thursday:
Read more
Merck KGaA sees gain in adj EBITDA of up to 18.5 pct
FRANKFURT, May 19 (Reuters) - German drugs and chemicals
maker Merck KGaA expects adjusted core earnings to
increase by up to 18.5 percent this year, helped by additional
profit from a takeover of lab supplies maker Sigma-Aldrich.
Read more
maker Merck KGaA expects adjusted core earnings to
increase by up to 18.5 percent this year, helped by additional
profit from a takeover of lab supplies maker Sigma-Aldrich.
Read more
HK Exchange says 16 firms buy back shares
HONG KONG, May 19 (Reuters) - The Hong Kong stock exchange said on Thursday
16 companies had repurchased their ordinary shares in the market.
The following is a table regarding share buybacks:
Company name Date of No. of Highest Lowest
(Stock code) Repurchase Securities Price per Price per
Repurchased share share
ALLIED GROUP 18/05/2016 6,000 HK$38.1 N/A
Read more
16 companies had repurchased their ordinary shares in the market.
The following is a table regarding share buybacks:
Company name Date of No. of Highest Lowest
(Stock code) Repurchase Securities Price per Price per
Repurchased share share
ALLIED GROUP 18/05/2016 6,000 HK$38.1 N/A
Read more
BRIEF-AmCad BioMed's product AmCAD-UV gets marketing authorization in Europe
* Says it got marketing authorization in Europe for its
product AmCAD-UV, which is used for early diagnosis of breast
cancer
Read more
product AmCAD-UV, which is used for early diagnosis of breast
cancer
Read more
UPDATE 1-Bayer makes preliminary offer to buy Monsanto
* Tie-up could raise US antitrust concerns - experts
(Recasts, adds Monsanto comment, industry background)
Read more
(Recasts, adds Monsanto comment, industry background)
Read more
BRIEF-Fuan Pharmaceutical Group to pay 2015 dividend on May 25
* Says it will pay cash dividend of 1 yuan per 10 shares
(before tax) to shareholders of record on May 24, for 2015
Read more
(before tax) to shareholders of record on May 24, for 2015
Read more
BRIEF- says 2015 dividend payment date
* Says it will pay a cash dividend of 3 yuan (pre-tax) for
every 10 shares and use additional paid-in capital to distribute
10 new shares for every 10 shares to shareholders of record on
May 25, for 2015
Read more
every 10 shares and use additional paid-in capital to distribute
10 new shares for every 10 shares to shareholders of record on
May 25, for 2015
Read more
BRIEF-Chugai Pharmaceutical announces results of Japanese phase III study of Alecensa
* Announced results of Japanese phase III study of Alecensa
in Alk fusion gene positive non-small cell lung cancer
Read more
in Alk fusion gene positive non-small cell lung cancer
Read more
U.S. House approves $622 million to combat Zika virus
WASHINGTON, May 18 (Reuters) - The U.S. House of
Representatives passed a bill on Wednesday to provide $622.1
million to control the spread of the Zika virus, far below
President Barack Obama's request and lower than Senate
legislation.
Read more
Representatives passed a bill on Wednesday to provide $622.1
million to control the spread of the Zika virus, far below
President Barack Obama's request and lower than Senate
legislation.
Read more
UPDATE 1-Activist investor heavyweights form new lobbying arm
NEW YORK, May 18 (Reuters) - A group of hedge funds have
formed a new lobbying arm to promote the benefits of shareholder
activism across the U.S. economy, as U.S. politicians turn up
the heat on activist investors.
Read more
formed a new lobbying arm to promote the benefits of shareholder
activism across the U.S. economy, as U.S. politicians turn up
the heat on activist investors.
Read more
BRIEF-VWR Corporation announces offering of 8 mln shares by selling stockholder
* VWR corporation announces offering of 8,000,000 shares by selling
stockholder
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1 646 223 8780)
Read more
stockholder
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1 646 223 8780)
Read more
Shkreli's former company beats Impax demand to block drug sales
NEW YORK, May 18 (Reuters) - Turing Pharmaceuticals does not
have to recall thousands of bottles of a life-saving medicine
that became the flashpoint of a pricing controversy after former
Chief Executive Martin Shkreli raised its price by over 5,000
percent, a U.S. judge ruled on Wednesday.
Read more
have to recall thousands of bottles of a life-saving medicine
that became the flashpoint of a pricing controversy after former
Chief Executive Martin Shkreli raised its price by over 5,000
percent, a U.S. judge ruled on Wednesday.
Read more
BRIEF-ImmunoGen reports positive early-stage data on ovarian cancer drug
* Reports efficacy and safety data from a 46 patient cohort
of mirvetuximab soravtansine in fr-positive ovarian cancer
Read more
of mirvetuximab soravtansine in fr-positive ovarian cancer
Read more
Pfizer says will present data on 6 drugs at ASCO meeting
* Pfizer to present data from six compounds including
daratumumab and ibrutinib at the 2016 American Society Of
Clinical Oncology (ASCO) annual meeting
Source text for Eikon:
Further company coverage:
Read more
daratumumab and ibrutinib at the 2016 American Society Of
Clinical Oncology (ASCO) annual meeting
Source text for Eikon:
Further company coverage:
Read more
BRIEF-J&J expects surgical robotics system to be working by year end
* Expects its surgical robotics system to be working by year
end, become eventual second approved surgical robotics system
Read more
end, become eventual second approved surgical robotics system
Read more
Deals of the day-Mergers and acquisitions
May 18 (Reuters) - The following bids, mergers, acquisitions
and disposals were reported by 1600 GMT on Wednesday:
Read more
and disposals were reported by 1600 GMT on Wednesday:
Read more
GE, Cisco, Airbus and others call for Britain to stay in EU-FT
May 18 (Reuters) - The heads of GE, Cisco,
Mars, EMC and Airbus, as well as Michael
Bloomberg, have signed a plea for Britain to stay in the EU,
according to the Financial Times.
Read more
Mars, EMC and Airbus, as well as Michael
Bloomberg, have signed a plea for Britain to stay in the EU,
according to the Financial Times.
Read more
Medtronic cuts deals to boost less-invasive surgical business
May 18 (Reuters) - Medtronic Inc, the world's
largest standalone medical device maker, wants to slice deeper
into the minimally invasive surgical products market and is
buying its way in.
Read more
largest standalone medical device maker, wants to slice deeper
into the minimally invasive surgical products market and is
buying its way in.
Read more
UPDATE 1-Foxtons, Paddy Power Betfair investors back exec pay
May 18 (Reuters) - Shareholders of two London-listed
companies approved their directors' pay on Wednesday, rejecting
the recommendations of influential advisors in a sign that
dissatisfaction over high salaries has yet to result in
widespread change.
Read more
companies approved their directors' pay on Wednesday, rejecting
the recommendations of influential advisors in a sign that
dissatisfaction over high salaries has yet to result in
widespread change.
Read more
BRIEF-Heads of GE, Cisco, Mars, Airbus and Michael Bloomberg, have signed a plea for Britain to stay in the EU- FT
* Heads Of GE, Cisco, Mars, Airbus And Michael Bloomberg,
have signed a plea for Britain to stay in the EU- FT, citing
letter
Read more
have signed a plea for Britain to stay in the EU- FT, citing
letter
Read more
UPDATE 1-U.S. FDA approves Roche's immunotherapy for bladder cancer
May 18 (Reuters) - The U.S. Food and Drug Administration on
Wednesday granted accelerated approval for Roche Holding AG's
immunotherapy for the most common form of bladder
cancer, marking the company's entry into a lucrative class of
drugs.
Read more
Wednesday granted accelerated approval for Roche Holding AG's
immunotherapy for the most common form of bladder
cancer, marking the company's entry into a lucrative class of
drugs.
Read more
UPDATE 2-English doctors' union and government agree deal to end dispute
LONDON, May 18 (Reuters) - The union representing England's
doctors and the government said on Wednesday they had agreed a
deal to end a long-running standoff which led to their first
all-out strike in the nearly 70-year history of the state-run
National Health Service (NHS).
Read more
doctors and the government said on Wednesday they had agreed a
deal to end a long-running standoff which led to their first
all-out strike in the nearly 70-year history of the state-run
National Health Service (NHS).
Read more
UPDATE 1-General Electric reaffirms forecast despite weaker growth
NEW YORK, May 18 (Reuters) - General Electric Co
expects to hit this year's earnings targets despite tough
conditions in its oil and gas business, lower industrial margins
and slower revenue growth, Chief Executive Jeff Immelt said on
Wednesday.
Read more
expects to hit this year's earnings targets despite tough
conditions in its oil and gas business, lower industrial margins
and slower revenue growth, Chief Executive Jeff Immelt said on
Wednesday.
Read more
BRIEF-American Caresource says on May 17, received notification that Nasdaq panel determined to delist shares of co's stock
* On May 17, 2016, co got notification that nasdaq listing
qualifications hearings panel determined to delist shares of
co's stock
Source text (http://1.usa.gov/1NylFvh)
Further company coverage:
Read more
qualifications hearings panel determined to delist shares of
co's stock
Source text (http://1.usa.gov/1NylFvh)
Further company coverage:
Read more
UPDATE 1-HK regulator says Alibaba broke takeover rules with "special deal"
HONG KONG, May 18 (Reuters) - Hong Kong's securities
regulator said that Chinese e-commerce giant Alibaba Group
Holding Ltd breached takeover rules in the purchase of
a healthcare firm in 2014 because it also bought a company owned
by the brother of the healthcare firm's vice chairman on
"favourable terms."
Read more
regulator said that Chinese e-commerce giant Alibaba Group
Holding Ltd breached takeover rules in the purchase of
a healthcare firm in 2014 because it also bought a company owned
by the brother of the healthcare firm's vice chairman on
"favourable terms."
Read more
BRIEF-Cel-Sci enters agreement with healthcare institutional investor to purchase about 10 mln shares of common stock and warrants
* Agreement with healthcare institutional investor to
purchase about 10 million shares of common stock and warrants
Read more
purchase about 10 million shares of common stock and warrants
Read more
BRIEF-UK's CMA investigating Acadia Healthcare's Priory Group deal
* UK's CMA is investigating the completed acquisition by
Acadia Healthcare Company Inc of Priory Group No. 1
Limited
Link to press release: (http://bit.ly/1qtyvjc)
Further company coverage:
(Bengaluru Newsroom: +91 806 749 1136)
Read more
Acadia Healthcare Company Inc of Priory Group No. 1
Limited
Link to press release: (http://bit.ly/1qtyvjc)
Further company coverage:
(Bengaluru Newsroom: +91 806 749 1136)
Read more
BRIEF-Macrogenics enters into agreement with Janssen to develop new dart molecule for treatment of cancer
* May elect to fund a portion of late-stage development
costs in exchange for a U.S. and Canada profit share
Read more
costs in exchange for a U.S. and Canada profit share
Read more
BRIEF-Hybio Pharmaceutical receives patent license
* Says it received a patent license (No. ZL 2013 1 0074154.0
), for a purifying method of triptorelin, on May 17
Read more
), for a purifying method of triptorelin, on May 17
Read more
BRIEF-Harbin Gloria Pharmaceuticals to stop acquiring 51 pct stake in pharmaceutical company
* Says it signed an agreement to stop buying 51 percent
stake in a Hubei-based pharmaceutical company on May 12
Read more
stake in a Hubei-based pharmaceutical company on May 12
Read more
Novartis breast cancer drug set to take on Pfizer's Ibrance
May 18 (Reuters) - A clinical trial testing an experimental
breast cancer pill from Novartis has been stopped early
because of good results, boosting the Swiss company's efforts to
build up its oncology business.
Read more
breast cancer pill from Novartis has been stopped early
because of good results, boosting the Swiss company's efforts to
build up its oncology business.
Read more
BRIEF-Tus-Guhan Group to acquire 70 pct stake in Hengyang-based pharmaceuticals company
* Says it to invest 26 million yuan to acquire 70 percent
stake in a Hengyang-based pharmaceuticals company
Read more
stake in a Hengyang-based pharmaceuticals company
Read more
INSIGHT-Pascal Soriot's big experiment: reinventing AstraZeneca
LONDON, May 18 (Reuters) - AstraZeneca Chief
Executive Pascal Soriot is a big believer in science, and the
biggest experiment of his career is the reinvention of the
drugmaker.
Read more
Executive Pascal Soriot is a big believer in science, and the
biggest experiment of his career is the reinvention of the
drugmaker.
Read more
Tuesday, May 17, 2016
BRIEF-Sonova Holding posts FY EBITA of 430.6 mln Swiss francs
* FY group sales of 2,071.9 million Swiss francs ($2.11
billion) - up 5.8 pct in local currencies and 1.8 pct in Swiss
francs
Read more
billion) - up 5.8 pct in local currencies and 1.8 pct in Swiss
francs
Read more
Swiss stocks - Factors to watch on May 18
ZURICH, May 18 (Reuters) - The following are some of the
main factors expected to affect Swiss stocks on Wednesday.
Read more
main factors expected to affect Swiss stocks on Wednesday.
Read more
U.S. FDA approves first appetite-stimulating drug for dogs
May 17 (Reuters) - The U.S. Food and Drug Administration
approved the first drug to stimulate appetite in dogs, Aratana
Therapeutics Inc, which developed the treatment, said
on Tuesday.
Read more
approved the first drug to stimulate appetite in dogs, Aratana
Therapeutics Inc, which developed the treatment, said
on Tuesday.
Read more
DIARY-Malaysia 2016 corporate earnings
Following is a list of release dates for the quarterly earnings
of some top Malaysia-listed companies.
To submit a date, email: ananthalakshmi.as@tr.com
Company RIC PERIOD DATE
AirAsia Bhd Q1 May 27
AMMB Holdings Bhd Q4 May 20-24
Astro Malaysia Holdings Bhd Q1 Jun 14-20
Axiata Group Bhd Q1 May 25
British American Tobacco
Read more
of some top Malaysia-listed companies.
To submit a date, email: ananthalakshmi.as@tr.com
Company RIC PERIOD DATE
AirAsia Bhd Q1 May 27
AMMB Holdings Bhd Q4 May 20-24
Astro Malaysia Holdings Bhd Q1 Jun 14-20
Axiata Group Bhd Q1 May 25
British American Tobacco
Read more
BRIEF-Aratana Therapeutics says FDA approved its drug for appetite stimulation in dogs
* Intends to commercially launch Entyce in conjunction with
North American Veterinary Conference in February 2017
Read more
North American Veterinary Conference in February 2017
Read more
BRIEF-Immunovaccine says secured $8 mln bought-deal private placement financing
* Underwriters will purchase, on a bought-deal basis, 14.55
million units of Immunovaccine at a price of $0.55 per unit
Read more
million units of Immunovaccine at a price of $0.55 per unit
Read more
BRIEF-Perkins Capital Management, Inc reports 10.2% stake in Nanosphere as of May 17, 2016 - SEC Filing
May 17 (Reuters) - Perkins Capital Management, Inc Had Previously Reported A
22.4% Stake In Nanosphere Inc As Of Dec 31, 2015
Read more
22.4% Stake In Nanosphere Inc As Of Dec 31, 2015
Read more
BRIEF-Aisling Capital II reports 7.4 pct passive stake in Cidara Therapeutics
* Aisling Capital II, LP reports 7.4% passive stake in
Cidara Therapeutics Inc as of December 31, 2015 - SEC Filing
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1 646 223 8780)
Read more
Cidara Therapeutics Inc as of December 31, 2015 - SEC Filing
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1 646 223 8780)
Read more
UPDATE 1-U.S. Senate set to approve $1.1 billion in Zika virus funding
WASHINGTON, May 17 (Reuters) - The U.S. Senate on Tuesday
cleared the way for approval of $1.1 billion in immediate funds
to battle the Zika virus that is linked to birth defects, well
above what is in legislation pending in the House of
Representatives.
Read more
cleared the way for approval of $1.1 billion in immediate funds
to battle the Zika virus that is linked to birth defects, well
above what is in legislation pending in the House of
Representatives.
Read more
J&J to stand behind talc's safety at upcoming trials -lawyer
NEW YORK, May 17 (Reuters) - Johnson & Johnson will
keep aruging in court that its talc-based powders are safe, an
outside lawyer who has defended the company in lawsuits said,
even after losing two multimillion-dollar verdicts to plaintiffs
who alleged that J&J Baby Powder and Shower to Shower caused
ovarian cancer.
Read more
keep aruging in court that its talc-based powders are safe, an
outside lawyer who has defended the company in lawsuits said,
even after losing two multimillion-dollar verdicts to plaintiffs
who alleged that J&J Baby Powder and Shower to Shower caused
ovarian cancer.
Read more
U.S. states' unfunded pension costs near $1 trillion in 2013 -Pew
SAN FRANCISCO, May 17 (Reuters) - U.S. states owed $968
billion in unfunded pension benefits for retirees in 2013, the
highest level in a decade, according to a report released
Tuesday by Pew Charitable Trusts.
Read more
billion in unfunded pension benefits for retirees in 2013, the
highest level in a decade, according to a report released
Tuesday by Pew Charitable Trusts.
Read more
BRIEF-Fitch says drug approvals driving targeted acquisitions in US pharma
* Large innovative U.S. Pharmaceutical companies are
expected to continue targeted acquisitions as need for larger
transactions has declined
Read more
expected to continue targeted acquisitions as need for larger
transactions has declined
Read more
UPDATE 2-Novartis splits drugs business into two, pharma chief to leave
* Existing cancer leader Strigini to head oncology
(Adds analyst comment, more on Novartis drug business)
Read more
(Adds analyst comment, more on Novartis drug business)
Read more
BRIEF-Bristol-Myers Squibb opens expanded biologics facility
* $280 million project increases workforce, "adds new
capabilities"
Source text for Eikon:
Further company coverage:
Read more
capabilities"
Source text for Eikon:
Further company coverage:
Read more
BRIEF-MiMedx says expects Q2 revenue to be in range of $55.7 mln to $57.0 mln
* Continue to expect Q2 of 2016 revenue to be in range of
$55.7 million to $57.0 million
Source text for Eikon:
Further company coverage:
Read more
$55.7 million to $57.0 million
Source text for Eikon:
Further company coverage:
Read more
European shares end little changed; Taylor Wimpey, Vodafone rise
LONDON/MILAN, May 17 (Reuters) - European shares steadied on
Tuesday with gains in companies such as Taylor Wimpey and
Vodafone following encouraging updates and a rally in
mining companies offset by a weaker auto sector.
Read more
Tuesday with gains in companies such as Taylor Wimpey and
Vodafone following encouraging updates and a rally in
mining companies offset by a weaker auto sector.
Read more
UPDATE 1-Walgreens makes overdose remedy prescription-free in New Mexico
May 17 (Reuters) - Walgreens Boots Alliance Inc. is
making the opioid antidote naloxone available without a
prescription in all its pharmacies in New Mexico, part of a plan
to make the drug readily available in 35 states by the end of
this year.
Read more
making the opioid antidote naloxone available without a
prescription in all its pharmacies in New Mexico, part of a plan
to make the drug readily available in 35 states by the end of
this year.
Read more
Genes tell how the giraffe got its long neck
LONDON, May 17 (Reuters) - Scientists have sequenced the
genome of the giraffe for the first time, uncovering DNA quirks
that help explain how the tallest animals on earth developed
their remarkably long necks.
Read more
genome of the giraffe for the first time, uncovering DNA quirks
that help explain how the tallest animals on earth developed
their remarkably long necks.
Read more
Coherus says U.S. Patent Office to review AbbVie's Humira
May 17 (Reuters) - Coherus BioSciences Inc said on
Tuesday the U.S. Patent and Trademark office had agreed to
review its petition to make a copy of AbbVie Inc's
top-selling artritis drug Humira.
Read more
Tuesday the U.S. Patent and Trademark office had agreed to
review its petition to make a copy of AbbVie Inc's
top-selling artritis drug Humira.
Read more
BRIEF-Neuca Med reaches 100 pct stake in Medica Pro Familia
* Following its squeeze-out offer, Neuca Med Sp. z o. o.
reaches 100 percent stake in the company
Read more
reaches 100 percent stake in the company
Read more
BRIEF-ANI Pharmaceuticals enters into exclusive distribution and supply agreement
* ANI Pharmaceuticals enters into exclusive distribution and
supply agreement for hydroxyprogesterone caproate injection usp
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1 646 223 8780)
Read more
supply agreement for hydroxyprogesterone caproate injection usp
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1 646 223 8780)
Read more
BRIEF-Cline Scientific signs agreement with distributor in France
* Says agreement has been signed with Interchim, a distributor of Life Science products on
French market for sale and distribution of Cline's entire product range
Read more
French market for sale and distribution of Cline's entire product range
Read more
BRIEF-Johnson & Johnson says collaborating with HP Inc's unit
* Johnson & Johnson announces collaboration with HP Inc.
subsidiary to create personalized health care solutions with 3D
printing technologies
Read more
subsidiary to create personalized health care solutions with 3D
printing technologies
Read more
BRIEF-Omeros enters debt financing transaction for $20 mln in additional funds
* Entered into an amendment to its existing credit facility
to provide company with an additional $20 million in
unrestricted cash
Read more
to provide company with an additional $20 million in
unrestricted cash
Read more
Subscribe to:
Posts (Atom)